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Abstract 
Prostate Cancer (PCa) is the most common non-cutaneous cancer in North 
American men. Multi-parametric magnatic resonance imaging (mpMRI) has the 
potential to be used as a non-invasive procedure to predict locations and prognosis 
of PCa. This study aims to examine non-cancerous pathology lesions and normal 
histology that could mimic cancer in mpMRI signals. This study includes 19 
radical prostatectomy specimens from the London Health Science Centre (LHSC) 
that were marked with 10 strand-shaped fiducials per specimen which were used 
as landmarks in histology processing and ex vivo MRI. Initial registration 
between fiducials on histology and MR images was performed followed by the 
development of an interactive digital technique for deformable registration of in 
vivo to ex vivo MRI with digital histopathology images. The relationship between 
MRI signals and non-cancerous abnormalities that could mimic PCa has not been 
tested previously in correlation with digital histopathology imaging. The 
unregistered mp-MRI images are contoured by 4 individual radiology observers 
according to the Prostate Imaging Reporting and Data System (PI-RADS). 
Analysis of the radiology data showed prostatic intraepithelial neoplasia (PIN), 
atrophy and benign prostatic hyperplasia (BPH) as main non-cancerous 
abnormalities responsible for cancer like signals on mpMRI. This study will help 
increase the accuracy of detecting PCa and play a role in the diagnosis and 
classification of confounders that mimic cancer in MR images. 
  
Keywords 
Prostate imaging, Prostate non-cancerous abnormalities, Prostate image 
regestirations, in-vivo prostate MRI, Prostate cancer.  
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Chapter 1 
1  Introduction 
1.1  Prostate Cancer Epidemiology 
Prostate cancer (PCa) is one of the most common cancers in North American men 
and the developed world. It is the second leading cause of cancer in men after skin 
cancer. According to the World Health Organization (WHO) (Globocan 2012), 
approximately that 1.1 million men worldwide were diagnosed with PCa with an 
estimated seventy-percent of cases established in developed countries (Figure 
1.1). These countries include USA, Canada, Australia, and New Zealand as well 
as Northern and Western European regions, which demonstrates the wide-ranging 
geographic variation of incidence with a twenty-five fold increase in incidence 
compared to developing countries [1].  
Several influences are responsible for incidence variations, including methods of 
data gathering and analysis, socio-economic status (SES) as well as access to the 
healthcare system. To further demonstrate this variation, the introduction of PCa 
screening tests with Prostate Specific Antigen (PSA) in the late 1980s and early 
1990s has significantly increased asymptomatic PCa cases detected in North 
America and the United Kingdom [2]. 
In 2012, it was estimated that 307,000 deaths were due to PCa, with a tenfold 
increase in the new incidence rate compare to the mortality rate [1]. Despite the 
increase in incidence rates of PCa in almost all countries, the mortality rate is 
higher in developing countries compared to a significant decline in developed 
countries [3] (Figure 1.2). The developed healthcare system is associated with a 
high level of PCa diagnosis accompanied by low mortality rate. The Canadian 
Cancer Society and The National Cancer Institute Surveillance, Epidemiology and 
End Results (SEER) in the USA estimated that new cases of diagnosed PCa for 
2015 were 24,000 in Canada and 220,800 in the USA. The mortality numbers 
were 4,100 in Canada and 27,540 in the USA. In Canada, PCa represents 24% of 
all cancer cases affecting men, compared to 13.3% in the USA.   
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Similarly, Canadian records reveal that PCa is responsible for 10% of all 
estimated cancer deaths compared to 4.7% in the USA with a five-year survival 
rate of 96% and 98.9% in Canada and the USA respectively [4, 5].  
With many risk factors associated with PCa, five leading causes have been 
discovered to have the strongest significance on PCa. These include 
race/ethnicity, age, family history, diet, and genetics, which will be discussed 
below [6]. 
1.1.1 Race/Ethnicity 
Several studies have concluded that black men or those with African descent have 
a higher risk of PCa compared to Caucasian men as well as a higher mortality rate 
with a 2.5-fold increase between the two racial groups [5]. Also, studies have 
shown that black men have a greater risk of being diagnosed with an advanced 
PCa grade at a younger age compared to Caucasian men in the same age groups.  
The lowest incidence of PCa was reported in Asian races and communities [1, 7-
9]. Data from the Detroit (SEER) registry confirms with the radical prostatectomy 
specimen analysis, that the cancer volume and Gleason score were higher in 
Black men.  They have an increased risk for more advanced and distant metastasis 
with a ratio of 4:1 compared to Caucasian men. These findings support the faster 
growth and transformation to clinically significant disease in Black men in 
comparison to Caucasian men [10].  
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(Figure 1.1) World map presenting the distribution of PCa incidence 
worldwide per 100,000 (Globocan 2012) [1] 
 
(Figure 1.2) International incidence and mortality of PCa worldwide per 
100,000. (Adopted from Globocan 2012) [1]. The graph presents a high incidence 
of PCa associated with low mortality in developed countries while developing 
countries sustained similar mortality rates despite low incidence rates. 
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1.1.2 Age 
Before the introduction of PSA screening, PCa was called the disease of old age. 
The risk of diagnosis of PCa in men under the age of forty is very low. It is 
estimated that 1 in 55 men will be diagnosed with PCa in the age group of 40-60 
years. However, this ratio will increase to 1 in 7 men in the age group of 60-80 
years [11].  Autopsy results in prostate tissue sampling illustrate that 75% of men 
over 80 years old will develop latent microscopic PCa at some point in their lives 
[12, 13]. Other studies have indicated that 26% of men over the age of 75 will be 
diagnosed with high-risk disease and clinically significant cancer.  Clinically 
significant cancer is defined as cancer with a volume of more than 0.5 cm3 and/or 
a Gleason score of more than 6 [14].  Advanced age at the diagnosis of PCa is one 
of the major risk factors for increased Prostate Cancer-Specific Mortality (PCSM) 
[15].  
1.1.3 Family and Socioeconomic Status 
The family history of PCa is another well-known risk factor that presents a 
sufficient warrant for early screening and close monitoring to detect early PCa 
when it arises.  Studies demonstrated that the risk of PCa is higher with brothers 
involvement than father involvement [16]. The family history of PCa is a greater 
risk factor for a more fatal and aggressive disease than for the isolated incidence 
of PCa, which points to the association of fatal PCa to a genetic subgroup [17]. 
However, PCa risk factors are more complicated than initially thought. It has been 
reported that higher Socioeconomic Status (SES) groups demonstrate high 
incidents of PCa with a low mortality rate across all racial and ethnic groups [18].  
Research studies report the early detection of PCa is possible due to the increase 
of frequent screening and an advanced health care system.  Studies have also 
indicated that regular screening is responsible for a small percentage of discovery. 
Additional factors should be considered and examined carefully for further 
understanding of the Socioeconomic Status and its relation to a higher PCa 
incidence [19].   
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1.1.4 Diet 
The fourth factor is the type of diet patients follow and its relationship to PCa 
incidence. Diets that contain a high fiber content such as vegetables and low fat 
have been associated with a decreased incidence of PCa. However, diets that 
involve high caloric content fatty foods such as red meat, dairy products and 
calcium from dairy products were also associated with increased incidence of PCa 
[20]. Some authors report that the consumption of fish three times or more per 
week was associated with a decreased risk of PCa as well as lowering the chance 
of metastatic disease development [21]. The exact correlation between types of 
food and PCa is still unknown with unclear pathway. Further examinations should 
address these correlations in more detail. 
Selenium was initially considered to lower the incidence of PCa. Results from 
other studies presented a moderate decrease in PCa risk with high serum selenium 
intake [22].  However, additional studies failed to replicate these findings and 
suggested no association between PCa and selenium serum level [23]. In recent 
cohort studies involving selenium and Vitamin E in a chemopreventive nutrient 
trial, no associations were discovered between serum selenium level and PCa [24, 
25]. 
1.1.5 Obesity 
Obesity is one of the public health challenges that society faces, as it has 
increased rapidly among the general population. Obesity is related to various 
diseases and types of cancer (e.g. breast and colon cancer). Obesity was not 
considered as a risk factor for PCa until recently. Obese men would have a higher 
risk of aggressive diseases with a lower chance of nonaggressive diseases if they 
were affected with PCa [26, 27]. This finding is potentially biased due to the 
difficulty of diagnosing PCa in obese men. To briefly explain, obese men have a 
larger volume of blood compared to non-obese men, this, in turn, will influence 
the PSA serum level to the lower range. Larger prostate sizes in obese men have a 
higher chance of missing the tumour during biopsies.  Obesity has also been 
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found to have an adverse impact on the sensitivity of digital rectal exams (DRE) 
[28, 29]. 
Obesity does not only affect the diagnosis of PCa, but it has an impact on 
treatment options and outcomes. After a prostatectomy and external radiation 
therapy, obesity was linked to biochemical failure. Furthermore, obesity is 
associated with a greater rate of complications and poor side effects after 
androgen-deprivation therapy as well as higher rate of PCSM [30, 31]. Obesity 
has been linked to increasing serum Insulin-like Growth Hormone (IGF-1), which 
has a strong linkage to increasing PCa risk [32].  
1.2 Anatomy and Histology of Prostate Gland 
1.2.1 Prostate Gland Anatomy 
The prostate gland is one of three accessory glands of the male genital 
reproductive system besides seminal vesicles and bulbourethral (Cowper’s) gland. 
It is a funnel-shaped organ, located in the true anatomical pelvic boundary. The 
prostate base is immediately below the bladder neck, and the apex is just above 
the urogenital diaphragm. The proximal half of prostatic urethra runs steeply 
downwards and forward through the center of the gland, then at the level of 
verumontanum (mid prostatic urethra) it twists anteriorly [33]. The anterior 
prostate surface is slightly concave and is located behind the pubic bone and 
connected to it with the puboprostatic ligament. The posterior surface is 
horizontal with a midline depression in contact with rectal ampulla. The prostate 
is separated from the rectum by a dual film thin like fascia termed “Denonvillier’s 
Fascia.” Extraperitoneal fat surrounds the prostate in the space of Retzius 
anteriorly, where the prostatic dorsal venous plexus is found. The venous plexus 
is responsible for the blood supply and drainage of the penis. The levator-ani 
muscles surround the lateral surface of the gland bilaterally. The prostate is 
pierced by ejaculatory ducts on the posterior surface laterally and run obliquely 
and forward towards the posterior surface of the urethra at the level of 
verumontanum where they join the prostatic urethra [34].  
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The essential and central landmark of the prostate gland is the urethra, which has 
an average length of 3-4 cm and a mid-urethral 35° angulation anteriorly. The 
urethral curvature divides the urethra into two sides: proximal and distal with an 
almost identical length. The verumontanum structure arises from the posterior 
wall of the urethra where this bend occurs. It continues and points distally to form 
the crista urethralis [35] (Figure 1.3). The majority of prostatic acini and 
ejaculatory ducts open in the verumontanum. The periurethral glands of Littre, 
which have a smaller opening are found along the whole length of the urethra. A 
circumferential muscle sheath layer covers the entire urethra and is attached 
between the two urethral sphincters. Proximally, the circumferential sheath 
contains smooth muscle with the role of preventing retrograde ejaculations. 
Distally, the apex region consists of smooth and striated muscle, which has a 
primary role in micturition control [36]. 
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(Figure 1.3) The urethra structures at the level of verumontanum. Low 
magnification of a prostate tissue section with hematoxylin and eosin stain 
showing urethral structure at the level of verumontanum and crista urethralis, an 
opening site for prostatic glands and ejaculatory duct. 
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1.2.2 Embryology of the Prostate Gland 
The prostate gland and the adjacent structure develops from 2 different origins. 
The prostate gland arises from urogenital sinus that develops from epithelial buds, 
while the Seminal Vesicles (SV), Epididymis, Vas Deferens (VD) and Ejaculatory 
Ducts (ED) develop from the Mesonephric Duct (Wolffian duct). The 
mesenchyme stimulates the urogenital sinus epithelium proliferation, ductal 
morphogenesis, and differentiation. Through the feedback loop mechanism, the 
epithelial tissue signals the mesenchyme tissue (undifferentiated connective 
tissue) to proliferate and differentiate into smooth muscle cells around the 
epithelial ducts. This development is under the regulation of androgen produced 
from the testis, which is considered the growth factor promoter to the prostate 
gland [37, 38]. 
The mesenchymal tissues continue growing to evolve the dome-shaped base of 
the prostate. During the mesenchymal growth, the ejaculatory duct formation 
continues to grow and proliferate towards the future verumontanum structure at 
urethral midway. The area around the ejaculatory duct continues to proliferate and 
form the central zone of the prostate. By the 10th week of embryonic life, the 
epithelial buds begin to branch mainly from the posterior and lateral regions of 
the urethral wall. The prostate duct formations and solid epithelial tissue continue 
to grow after birth at a very slow rate with a constant prostate size (less than 2 cm 
in diameter) until puberty [35, 38]. By the age of 20, and under the effect of 
androgen on the prostate, the gland reaches approximately 20 g in weight and 
remains within this range until the age of 30. 
1.2.3 Microscopic Anatomy of the Prostate Gland 
According to Dr. McNeal’s model, the prostate gland is composed of glandular 
and non-glandular regions or districts that cannot be separated by gross anatomy. 
The glandular component contains Peripheral, Central and Transitional Zones that 
are only identified on a microscopic level.  The non-glandular tissues are anterior 
fibromuscular stroma and prostatic capsule. Additionally, McNeal includes the 
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periprostatic and striated sphincters, nerve and blood supply within the non-
glandular tissue component [39, 40].  
1.2.3.1 Peripheral Zone (PZ) 
The Peripheral Zone composes 70% of the prostate gland volume. It is the most 
common region for (chronic) Prostatitis, Prostatic Intraepithelial Neoplasia (PIN) 
and Carcinoma. It occupies the posterior, lateral and distal anterolateral area 
(apex) of the gland, which gives it a horseshoe shape. The peripheral zone ducts 
open into the urethra as a double row every 2 mm on the posterolateral surface for 
about 1.5 cm from the verumontanum proximally to the apex distally [36, 40].  
The coronal section of the prostate gland demonstrates that the ducts of the 
peripheral zone occupy the lateral area around the distal urethra extensively at a 
15° angle. The ducts are distant from the urethra toward the prostate capsule and 
have branches arched anteriorly and posteriorly giving origins to groups of acini. 
The acini are similar in shape and thickness. Also, the acini are distant from the 
urethra. Peripheral zone acini have a simple structure and are oval or rounded in 
shape surrounded by loose woven stroma and collagen (Figure 1.4) [33, 39, 40].  
1.2.3.2 Central Zone (CZ) 
The central zone composes 25% of the gland volume. It is responsible for 1-5% of 
the incidence of carcinoma and inflammation. The central zone is a cone-shaped 
structure that encloses the Ejaculatory Ducts (ED) with its base distal to the 
bladder neck, and its apex pointed at the verumontanum. The base of the prostate 
gland is formed mostly by the CZ. The ducts open in the verumontanum just 
around the ED orifices and fan out towards the base. The central zone acini 
display more complex structure than the peripheral and transitional zones. The 
acini are larger in size, particularly towards the capsule with papillary folding and 
intraluminal ridges, which resemble a cribriform appearance. This cribriform 
glandular structure shape is occasionally misidentified as Prostatic Intraepithelial 
Neoplasia (PIN). The central zone has a higher stromal to epithelial ratio 
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compared to other prostatic tissues. The stroma consists of compact interlacing 
smooth muscle bundles (Figure 1.5) [33, 36, 40].  
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(Figure 1.4) Peripheral zone. Simple rounded or oval glands with loose woven 
stroma in between. 20X magnification power. 
 
(Figure 1.5) Central zone. Glands structures are more complex (Cribriform) with 
compact interlacing stromal appearance. 15X magnification. 
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1.2.3.3 Transition Zone (TZ) 
Initially, the Transition Zone (TZ) was not described by Dr. McNeal until 1978. 
He published a report in 1972 stating that Benign Prostatic Hyperplasia (BPH) 
arised from periurethral glands. He concluded that it is a benign nodular 
hyperplasia of the prostatic urethra [41]. The new anatomical concept emerged 
after the fundamental change in Dr. McNeal’s report in 1978 stating that the 
origin of BPH is in the transitional zone [42, 43]. The TZ surrounds the proximal 
prostatic urethra, forming about 5% of prostatic volume, however, it can grow 
significantly and become more than the remaining prostate tissue combined. The 
TZ ducts exit the urethra as a single slit on the posterolateral surface just proximal 
to urethral angulation occurrence. The ducts extend laterally and curve sharply 
anteriorly and branches in the direction of the bladder neck. There is a clear 
boundary between TZ and the residual glandular tissue made by fibromuscular 
tissue, which enables its visualizations by transrectal ultrasound. The acinar 
component of the TZ is similar to the PZ with a small rounded or oval structure 
encircled by more compressed stroma composed of a compact, dense, interlacing 
smooth muscle bundle. This smooth muscle blends with pre-prostatic sphincter 
stroma and Anterior Fibromuscular Stroma (AFMS) [33, 40].  
Rather than BPH, the TZ is responsible for 20% of prostate carcinoma.  
Pathologists refer to PZ and CZ as outer prostate or non-transition zone and the 
TZ and AFMS as the inner prostate [44]. Transition zone cancer is usually large 
in volume with high PSA serum level, although it is accompanied by low Gleason 
score [45]. Cancer arising from TZ is associated with high risk of bladder neck 
involvement with anterior positive surgical margins and low risk for 
neurovascular bundle invasions, Extra Prostatic Extension (EPE) or Seminal 
Vesicles (SV) [45, 46]. 
1.2.3.4  Anterior Fibromuscular Stroma (AFMS) 
According to Dr. McNeal’s description, AFMS is an apron of wedge-like shaped 
tissue. It runs from the bladder neck over the anteromedial surface of the prostate 
proximally and becomes narrow distally to connect with the prostatic urethra at 
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the apex [40]. It is attached to the periprostatic sphincter and Transition zone from 
its posterior dorsal surface proximally, and the semicircular striated muscle 
towards the apex distally. The lateral margin of AFMS interlaces with prostatic 
capsule laterally above, providing cover to most of the anterior margin of the PZ. 
The AFS structure is similar to the bladder neck with a large compact smooth 
muscle bundle. However, these smooth muscle bundles are more randomly 
oriented and are divided in between with bands of dense fibrous tissue [33, 36, 
40]. 
1.2.3.5 Prostate Capsule 
The capsule of the prostate gland consists of a dual layer, a smooth muscle layer 
located internally with the collagen layers externally.  The inner smooth muscle 
layer grows transversely and inwards to blend with the smooth muscle 
surrounding the prostatic glandular acini. Clear identifications between the two 
layers is quite difficult even with the assistance of viewing these layers on the 
microscopic level [35]. To further explain this difficulty, the multilayer 
collagenous fascia surrounds the gland, which varies in thickness across the 
different areas of the prostate. This fascia may blend with the capsule depending 
on the location. The capsule is ill-differentiated and contains varied tissue 
between smooth muscles, striated muscles and fibrous tissue in the region of the 
apex. The inconsistency of prostate capsule structure leads to not being 
considered as a real anatomical feature [47, 48]. Since the prostate gland is 
surrounded by abundant amounts of adipose tissue, pathologists use this as a 
landmark for extra-prostatic tissue identification and the assessment of cancer 
spreading outside the gland in prostate biopsy or total prostatectomy specimens. 
1.2.4 Vascular Supply 
The arterial supply to the prostate originates from two sets of arteries on each 
side, known as the superior and inferior prostatic pedicles. Commonly, the 
superior prostatic pedicle (prostate artery) is a branch of the prostatic-vesicular 
artery that supplies the inferior bladder portion and seminal vesicles.  The origin 
of the prostate artery is variable. For instance, the cadaveric specimens study 
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demonstrated that the prostate artery might originate from other roots [49]. The 
prostate artery then divides into two branches adjacent to the base of the prostate 
gland laterally, the urethral artery (medial branch) and the capsular artery (lateral 
branch). The urethral artery is responsible for blood supply to the proximal 
prostatic urethra until the crista urethralis, transitional zone, and paraurethral 
glands. It penetrates the gland on prostatovesicular junction proceeding in a 
perpendicular course in relation to the urethra before having a 90° angle turn to 
run parallel to it.  The capsular artery has a caudal descending direction towards 
the apex and external to the prostatic capsule. Capsular artery has perforated 
branches that penetrated the prostatic capsule providing blood supply to the 
prostate capsule, central zone, and distal urethra. The capsular artery receives 
various anastomosis from the inferior prostatic pedicle branch after forming 
plexus around the distal prostate-urethral junctions [34, 50, 51]. 
1.2.5 Neurovascular Bundles of the Prostate  
The prostate neurovascular bundles are formed on a groove between the 
posterolateral borders of the prostate anteriorly and rectum posteriorly. It consists 
of the cavernous nerves that arise from the pelvic plexus to supply corpora 
cavernosa and corpora spongiosum after entering the helium of the penis inferior 
to the pubic bone. It has a major role in erectile function. This gives the bundle its 
significant surgical landmark due to the direct impact on post-surgical recovery as 
well as resuming erectile function and sexual activity.  The cavernous nerves are 
joined by arterial and venous branches from the prostatovesicular artery and veins 
admixed together to form the bundle. The bundles run between the prostatic fascia 
medially, and levator ani muscle fascia laterally.  The cavernous nerves contain 
sympathetic fibres originating from T11 to L2 ganglia as well as parasympathetic 
elements originating from ventral rami of S3 and S4 [34, 52]. 
1.2.6 Normal Histology of the Prostate Gland 
The essential physiological function of the prostate gland is to sustain nutrition to 
sperms during ejaculation with quick and efficient ejections of small volumes of 
fluid. The prostate has a large storage capacity with a low secretory volume. The 
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muscular component allows the gland to carry out these functions [35]. The ducts 
and acini are both lined with tall columnar secretory epithelium cells with pale to 
clear cytoplasm, secretory vacuoles, and dark nuclei. The secretory vacuoles are 
tightly packed in PZ and TZ; however, they are wider and less dense in the CZ 
[33, 35, 39]. Secretory cells produce Prostate-Specific Antigen (PSA) and 
Prostate Specific Acid Phosphatase (PSAP) from all prostate zones. Also, they 
produce pepsinogen II, lactoferrin, and plasminogen activator from the CZ. They 
stain positive with PSA and PSAP and negative with high molecular weight 
cytokeratin stain due to the lack of immunoreactivity [35].   
The secretory cells are found on the layer of basal cells, which are isolated from 
the basement membrane and stroma. Basal cells are flattened, elongated in shape, 
with slender dark nuclei and are progressively scant or with no cytoplasm 
comparable to fibroblasts. They are arranged parallel to the basement membrane. 
Occasionally, the basal cells are not seen, or they may be presented partially 
around the ducts and acini of the prostate gland. Basal cells stain positive for high 
molecular weight cytokeratin or P63 stain. They are absent in the existence of 
adenocarcinoma.  
The distal ducts near the urethra are lined with urothelial cell similar to the 
urethral epithelium. The urothelium is a spindle-shaped like cell with scant 
cytoplasm. The nucleus sustains a nuclear groove. The long axes of these grooves 
are parallel to the basement membrane [35, 39]. 
The last epithelial cell type is endocrine-paracrine cells that has unknown 
physiologic functions. They are found between the basal and secretory cell with 
the lateral dendritic process [39]. These cells are not easily identified with routine 
Hematoxylin and Eosin staining (H&E), that require special 
immunohistochemical stains of antibodies like chromogranin A, serotonin, and 
neuron-specific enolase [53, 54]. Although, the paracrine cell function is still 
unknown, they contain serotonin granules and various peptide hormones such as 
somatostatin, calcitonin, and bombesin [33, 35, 39, 54].  
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1.2.7 Mimickers of Prostate Cancer 
Pathologists face a challenging task in diagnosing PCa, especially in a small 
glandular amount in well differentiating cancer lesions or other deviations from 
normal histology tissue. The mimickers are classified according to their glandular 
size in comparison to Gleason scoring. There are small, medium and large 
glandular size mimickers. However, the majority of mimickers fall into the small 
gland category [55]. 
The following section discusses three noncancerous pathological lesions. We have 
observed that atrophy, Prostatic Intraepithelial Neoplasia (PIN), and Benign 
Prostatic Hyperplasia (BPH) were the major confounders of prostate cancer on 
MRI (discussed further in section 3). These lesions can result in a false positive 
cancerous-like signal in MRI on prostate gland images. 
1.2.7.1 Atrophy 
Atrophy is one of the most common discoveries in prostate tissue during biopsy 
or retrieval of the whole prostate specimen from radical prostatectomy. There are 
two main characteristic types of atrophy, diffuse and focal. Androgen deprivation 
is responsible for diffuse atrophy whether through orchiectomy, surgically or 
chemically through antiandrogen or luteinizing releasing hormone agonists [56]. 
Focal Atrophy has no known link to androgen deprivation, however, earlier 
studies refer to focal atrophy as a part of aging. Other research studies have 
indicated that focal atrophy could be a result of either acute or chronic 
inflammation [35, 57].  
The focal atrophic glands are typically heterogeneous patches, distorted and 
relatively small in size. They are accompanied by flattened epithelium and 
hyperchromatic nuclei. Some focal atrophic acini are present with the complete 
lack of a basal cell layer [56]. There are multiple variants for atrophic gland 
subtypes. Nevertheless, these subtypes share the same main histologic features. 
No challenges exist in identifying atrophic glands with high power magnifications 
except for Post-Atrophic Hyperplasia (PAH). The challenges the pathologists face 
in recognizing PAH are owed to the increase of the cytoplasmic basophilic 
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appearance and increase in acinar architecture. Other types of atrophic glands are 
conceivably mistaken with adenocarcinoma on low power magnifications. Four 
distinctive variants of prostate focal atrophy are discussed further.  
1.2.7.1.1 Simple Atrophy (SA) 
The first typical variant and the most common type of atrophy is known as the 
Simple Atrophy (SA).  The acini appear basophilic on a low-power magnification 
due to the diminished amount of cytoplasm. Although the acini appearance are 
irregular and angulated, they still appear within a relative average calibre. The 
cells are reduced in the cytoplasm with no change to the nucleus size and shape 
with the nucleoli appearing smaller with chronic inflammation. In summary, they 
are mimicking adenocarcinoma (Figure 1.6) [35, 56]. 
1.2.7.1.2 Post-Atrophic Hyperplasia (PAH) 
The acini in PAH are small and rounded with a lobular arrangement (Figure 1.7). 
They are often accompanied by dilated ducts called feeder ducts, resulting in the 
appearance of resting breast lobules. Therefore, some authors and pathologists 
termed PAH as lobular atrophy [56]. PAH is basophilic in appearance with low 
cuboidal cell shape, scant cytoplasm and a small to a medium-sized nucleus with 
mild to moderate enlargements compared to adjacent normal epithelial cells. This 
results in the confusion with adenocarcinoma [35, 56, 58]. A tight arrangement of 
multiple small acini raises the impression of tissue proliferation when relating to 
normal tissue and hyperplasia expression [59]. 
Although the basal cell layer is present in PAH acini, it is rarely identified with a 
light microscope using a hematoxylin and eosin stain. The basal cells are present 
and appear in a distorted and fragmented layer with the use of 
immunohistochemically high-molecular-weight cytokeratin stain. The PAH is 
associated with stromal involvement. Stromal changes are varied and are capable 
in presenting as a smooth muscle atrophy to dense sclerotic changes that have a 
significant impact on acini shape and luminal space [58]. 
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PAH is commonly associated with chronic inflammatory cells in the adjacent 
stroma or the luminal space [56]. PAH represents the most extreme form of 
morphological changes of atrophic acini, which may be misdiagnosed as an 
adenocarcinoma followed by unnecessary treatment intervention. 
1.2.7.1.3 Simple Atrophy with a Cystic Formation 
The acini in simple atrophy with cystic formation reveal that shape and diameter 
vary. They range from a small to large calibre that produce a sieve-like 
appearance in the gross sections as well as cystic-like appearances under the 
microscope. The acini are arranged tightly with little to no stromal in-between. 
The cells have a little cytoplasm. There is no relation observed between simple 
atrophy with cystic formation and chronic inflammation [35, 56] (Figure 1.8).  
1.2.7.1.4 Partial Atrophy  
In contrast with the various types of atrophy, partial atrophy acini have a non-
basophilic appearance on low magnification. The cytoplasm is reduced in the 
partial atrophic epithelial cells compared to the normal glandular epithelium. The 
majority of cytoplasm commonly presents laterally to the nucleus leading to 
enhanced internuclear spaces. This results in a low-to-pale appearance on low 
power magnification (Figure 1.9). The partial atrophic glands may become 
present in small to medium sizes with intraluminal dark pinkish or crystalloid 
secretion that could mimic adenocarcinoma of the prostate. Partial atrophy is 
frequently viewed as simple atrophy presenting the proposition to consider that 
partial atrophy as a stage of atrophic changes [35, 56]. 
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(Figure 1.6): Simple Atrophy. Angulated glands with basophilic appearance 
with very low to no cytoplasm with normal size, dark nuclei. 20X magnification. 
         
(Figure 1.7) Post-Atrophic Hyperplasia (PAH). Low power image shows a 
central dilated duct (feeding duct) surrounded by atrophic acini.  
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(Figure 1.8) Simple atrophy with cystic formation. Simple cystic atrophy, 
distinctive with medium to large calibre glands, rounded in shape with no or very 
little cytoplasm. 10X magnification. 
          
(Figure 1.9) Partial atrophy. Pale cytoplasm is laterally positioned with 
increased internuclear distance. Glands are also with pink to eosinophilic 
Intraluminal secretion. 15X magnification. 
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1.2.7.2 Prostatic Intraepithelial Neoplasia (PIN) 
Historically, McNeal and Bostwick described PIN as premalignant lesions and 
identified it as a  intraductal dysplasia [60]. Previously, PIN was classified into 
three categories according to epithelial dysplasia; mild, moderate and severe. 
Pathologists currently use a newer classification, which includes only two classes, 
low-grade, and High-Grade PIN (HGPIN). HGPIN is considered the most 
acceptable PCa precursor by many Pathologists. With a morphology similar to 
prostate adenocarcinoma, HGPIN denotes a pre-invasive state to a cellular 
hyperplasia of prostatic gland [61]. Not only do PIN and PCa share comparable 
morphological features, but they also have similar epidemiological criteria 
regarding age and race. A strong relationship is identified between advanced age 
and incidence, size, and multifocality of PIN diagnosis. PIN has been reported in 
men as early as 20 years of age, however, these findings were associated with to 
low-grade PIN [62]. HGPIN and PCa have a high incidental rate in African 
American men compared to Caucasian men and other race groups. In contrast, no 
significant associations have been found between HGPIN and the increase of free 
or total PSA serum level [61-64]. This limitation leads to the conclusion that 
prostate biopsy is the only current method of detection and screening for HGPIN. 
The specific criteria to distinguish between low and high-grade PIN includes 
prominent nucleoli and more atypia in HGPIN [60]. A wide range of intra-
observer variability exists with over or underdiagnosis of HGPIN in Pathologists’ 
reports.  
Low-grade PIN glands demonstrate slight epithelial proliferation and crowding 
with some irregular spacing. The nucleus criteria includes a slight enlargement 
accompanied by a thin membrane and normal chromatin activity. The basement 
membrane and basal cell layer are continuous and intact [65].  
However, HGPIN consists of benign glands with some architecture abnormalities 
in prostate glands acini, the main feature of its diagnosis is nuclear atypia with 
close features to cancerous cells rather than normal epithelium. 
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Extensive volume and multifocal HGPIN have a high predictive value for 
increasing frequency, amount, and severity in the presence of PCa [61]. Both 
HGPIN and PCa have a greater chance arising from the peripheral zone. They 
demonstrate similar nuclear features and correlate with epithelial dysplasia [65]. 
HGPIN and PCa share heterogeneous features with multifocal presence. PIN 
associated with increased angiogenesis similar to changes that occur with PCa, 
which is used as evidence to consider PIN as a PCa precursor. These 
characteristics in HGPIN make it one of the mandatory standard diagnosis 
remarks in prostate biopsy or radical prostatectomy pathology reports [61]. 
HGPIN glands display glandular enlargement with four main patterns, tufting 
(most common), flat, papillary, or cribriform. Unusual patterns include signet ring 
cell, foamy glands, small cell (neuroendocrine), hobnail, and squamoid [66]. 
There is no clinical significance between patterns. The majority of cases will 
demonstrate most of the histological patterns existing at the same time. The acini 
are separated by a different amount of stroma. Their characteristic features 
include nuclear enlargement and overlap with hyperchromatic evidence add-ons 
to the increase of nuclear-cytoplasmic ratio, epithelial hyperplasia, and 
amphophilic cytoplasm. The nuclear membrane gets thickened with enlarged 
nucleoli. These features are responsible for the PIN basophilic appearance on low 
magnification power. The basement membrane is present with disruption to the 
basal cells [65]. The HGPIN nuclei are located closer to the gland’s center 
compared to the nuclei close to the basement membrane in normal glands [60]. 
The specific immunohistochemical staining (High molecular weight cytokeratins, 
CK5, p63) is used to distinguish between HGPIN and in particular with the 
cribriform pattern of Gleason grade 4 in the prostate biopsy (Figure 1.10). PIN  
glands show micropapillary form similar to breast micropapillary intraductal 
carcinoma with more crowded and piled up nuclei.  
The primary incidence of the HGPIN finding and risk of PCa are assumed to be a 
50% chance on prostate biopsy. However, later studies showed that the median 
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risk of diagnosing PCa after HGPIN detection is about 21% [67, 68]. The 
majority of Pathologists agree that the detection of HGPIN on needle biopsy 
warrants a follow-up biopsy [69]. 
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(Figure 1.10) Histopathology digital images for a whole-mount prostate 
section with PIN features. (A) Prostate whole-mount section image stained with 
high molecular weight cytokeratin immunohistochemical stain (CK) compared to 
the same prostate section stained with Hematoxylin & Eosin staining (H & E) (B). 
(C) a 10 times power zoom shows the same section area containing glands with 
the cribriform type of high grade prostatic intraepithelial neoplasia stained 
positive with cytokeratin in the image (C) and (H & E) staining in the image (D). 
A high-power zoom of the same section with the area containing PIN, stained 
with cytokeratin in the image (E) and with (H & E) stain on image (F). Note PIN 
glands stain positive with cytokeratin (dark blue arrow) compared to the negative 
stain with prostate adenocarcinoma glands (cyan arrow) in the image (E). 
 
 
 
 
 
 
 
 
 
 
 
 
27 
 
 
1.2.7.3 Benign Prostatic Hyperplasia (BPH) 
Nodular hyperplasia or BPH is considered one of the benign conditions of the 
prostate. It involves an enlargement of the transitional zone and the area around 
the urethra due to the proliferation of epithelium and stromal tissue. This 
proliferation creates pressure on the prostatic urethra along with prostatic 
sphincter. The significant pressure is responsible for a set of symptoms termed 
Lower Urinary Tract Symptoms (LUTS). These symptoms include increased 
urinary frequency, urgency, weak urine stream with diminished force and size, 
incomplete void and nocturia [70]. The transitional zone hyperplasia also 
accounts for prostate gland outline deformity. The enlargement of the transitional 
zone in the direction of the apex leads to diminishing the anterior fibromuscular 
stroma due to stretching and increasing the anteroposterior gland dimension. 
Additionally, the peripheral zone is compressed and thinning due to lateral growth 
resulting in increasing the gland width [35, 71].  
BPH is predominant at an advanced age sharing some similarity with prostate 
cancer. However, it is not considered as a PCa precursor. 10% of the BPH cases 
are found to be associated with PCa, and they are discovered accidentally during 
transurethral prostatectomy resection procedures [72]. An advanced age increases 
the risk for BPH and PCa, in addition, both might respond well to androgen 
deprivation [73]. 
BPH usually replaces the entire transitional zone (Figure 1.11) and consist of 
multiple, individual, nodules, that differ in size and shape. Grossly, these nodules 
are varied between soft, firm or rubbery in consistency and yellowish-gray in 
color. There are two subtypes of BPH, depending on predominant tissue 
proliferation, epithelial hyperplasia (Figure 1.12), and stromal hyperplasia 
(Figure 1.13). Grossly, the epithelial nodules have a spongy like appearance that 
bulges on the cut surface which is oozing a pale, white, and watery like fluid. The 
predominant stromal BPH consists of fibrous connective tissue and smooth 
muscle present with trabeculation or diffuse enlargement with no nodule 
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formation. The majority of BPH nodules contain all elements with varying extent 
in each nodule. 
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(Figure 1.11) Whole-mount prostate formalin block with BPH features and 
their digital (H&E) histopathology image. Whole-mount prostate formalin 
block (A) shows two yellowish-grayish large transitional zone hyperplasia with a 
spongy appearance (blue arrows) adjacent to the Urethra (white arrow) bilaterally. 
Right side nodule is more significant than the Left side. The same section 
presented in image (B) with Hematoxylin and Eosin stain (H&E) demonstrates a 
large transitional zone with benign prostatic hyperplasia (blue arrows) on each 
side of the urethral structure (yellow arrow).  
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(Figure 1.12) The glandular element of BPH, also known as epithelial element 
in the transition zone of the prostate gland. 10X magnification 
       
(Figure 1.13) The stromal element of Benign Prostatic Hyperplasia (BPH). 
High power image showing stromal element in the transitional zone of the 
prostate gland consists of fibrous connective tissue and smooth muscle.  
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1.3 Screening 
Improvement in the management and treatment of cancer, in general, is owed to a 
unique collaboration between five disciplines including screening and early 
detection programs, imaging, surgery, chemotherapy, and radiation. In PCa, the 
current detection methods include Digital Rectal Exam (DRE), Prostate-Specific 
Antigen (PSA), which is a blood serum testing as initial screening followed by 
Transrectal Ultrasound (TRUS) guided biopsies.  
1.3.1 Prostate-Specific Antigen (PSA) 
Prostate-Specific Antigen (PSA) is a glycoprotein produced by the secretory 
epithelial cell in the prostate ducts and acini. PSA is also a serine protease of the 
Human Kallikrein family (HK-3). It is responsible for the release of spermatozoa 
from the seminal clots by dissolving and the breakdown of gel-forming proteins, 
improve sperm motility as well as soften the cervical mucus [74, 75]. 
PSA is synthesized as a proenzyme (pro-PSA) in normal and other pathological 
cells such as hypertrophy or cancer. The Pro-PSA is then secreted into the lumen 
of prostate ducts where it gets activated by removing the propeptide chain 
followed by inactivation of proteolysis. The active and inactive PSA leaks into the 
bloodstream through the capillary basement membrane after passing through the 
stroma and epithelial basement membrane. In the blood serum, the inactive PSA 
is unbounded and called (free-PSA) while the active form of PSA gets bounded 
by a protease inhibitor [76, 77]. Prostate cancer cells were found to produce more 
binding protein PSA. This lead to lower free-PSA in proportion to total PSA in 
prostate cancer patients [78]. 
The most commonly used value for PSA cutoff is 4 ng/ml, although this value is 
still controversial. The PCa probability with PSA level lower than 2 ng/ml is 
found to be around 2%. This probability is increased significantly to 18% with 
PSA levels from 2.5-4.0 ng/ml. The possibility of PCa is 22-27% for PSA values 
between 4.0 and 10.0 ng/ml, rising to 67% with PSA values more than 10.0 ng/ml 
[74]. Studies suggested lowering the PSA cutoff value to 2.5 ng/ml or even 
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further to 1.5 ng/ml to improve early cancer detection and a better outcome [79, 
80]. However, dropping the cutoff PSA value will lead to increase the sensitivity 
and decrease the specificity, leading to an increase in the number of unneccesary 
biopsies [77, 80, 81]. 
Many factors should be measured for the optimum cutoff value for PSA. Factors 
such as age, race and medications can have a significant impact on the range of 
normal PSA values. 
1.3.1.1 Age and Race-Specific PSA Range 
The prostate gland tends to increase in size with age, affecting the amount of PSA 
produced by normal epithelial cells.  As a result, it has been proposed that in men 
with no prostate cancer, a different standard reference range for each age group 
should be used (Table 1.1) [82, 83]. The PSA value is also affected by various 
ethnic and racial groups. Men of African descent were found to have a higher 
PSA average compared to those from Caucasian and Asian roots [77, 83, 84]. 
Since PSA is produced by normal and pathological cells, noncancerous lesions 
could affect the level of PSA, but not to the same extent as cancer cells. PSA 
could also be influenced by physiological functions like ejaculation, which 
increases the PSA level.  Prostatitis, infarction, and BPH were found to increase 
PSA level. Locally invasive procedures such as prostate needle biopsies were also  
are found to increase PSA levels [76].  
Medications such as 5-alpha-reductase inhibitor and Finasteride were used in the 
treatment of BPH and hair loss respectively were found to lower PSA levels by 
50% with minimal effect on PSA produced by cancer cells. These medications 
could be used to enhance the efficacy of serum PSA testing to minimize the 
number of unnecessary prostate biopsies [85]. 
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Age PSA Specific 
reference range 
(ng/ml) 
40-49 0.0-2.5 
50-59 0.0-3.5 
60-69 0.0-4.5 
70-79 0.0-6.5 
(Table 1.1) Proposed PSA Age-Specific reference range [82] 
 
 
 
 
 
 
 
 
  
35 
 
 
1.3.1.2 Free vs. Total PSA 
Currently, the introduction of free PSA to total PSA ratio has improved the 
specificity of PSA in predicting and detecting  PCa, in particular when total PSA 
is in a normal range (below 4 ng/mL) or in the gray zone (4-10 ng/mL). Men with 
PCa are found to have a lower percentage of free PSA compared to cancer-free 
men. The cutoff value of free PSA percentage around 25% or less was found to 
increase the risk of PCa by 95% and decrease unnecessary biopsies by 20% [86]. 
Other studies suggested adding the age as a considered influence [84]. In the 
circumstances of the standard Digital Rectal Exam (DRE) and PSA (4-10ng/mL), 
men with 70 years of age and above should use 16% of free PSA  compared to 
20% in men under 70 years old [87]. 
1.3.2 Prostate Cancer Diagnosis  
Prostate Cancer (PCa) diagnosis is made through histological assessment and 
evaluation following a prostate biopsy. Since most PCa arises from the peripheral 
zone, it is unusual for PCa to cause any symptoms unless they are locally invasive 
to the urethra or if it produced distant metastasis. Before the era of PSA, abnormal 
DRE was the only reason for the prostate biopsy. Currently, abnormal PSA alone 
is sufficient to warrant a prostate biopsy even though the DRE is normal.   
Prostate biopsy is achieved with the aid of Transrectal Ultrasound (TRUS), which 
can be used to assess the prostate volume as well as detect prostate lesions for 
biopsy. Any suspicious hypoechoic lesion within the prostate gland should be 
sampled, even though, not every hypoechoic lesion will be cancer positive. Some 
author proposed that only 18% of the hypoechoic lesions will produce positive 
tumour sampling [88]. 
Prostate biopsy was initially performed through a sextant pattern by obtaining one 
core bilaterally from the prostate gland base, mid-gland and apex. Increasing the 
number of core biopsies with more attention given to the lateral and apex zone 
sampling has increased the chance of cancer detection by 31% [89]. Many 
research studies focused on increasing the number of sampling cores with the 
relation to cancer detection rates. A 10-12 core biopsy pattern provides a balance 
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between cancer detection rate and lower morbidity and adverse effect rate [90, 
91]. Some authors have reported no extra benefits in cancer detection rate from 
increasing core sampling number more than 12 cores [89-91]; however, this is 
still controversial. 
Despite the chance of improvement in detecting PCa with an extended scheme of 
core sampling biopsy, it is still estimated to carry a false-negative rate. The 
detection rate in prostate biopsy reaches 39-52% using the assistance of MRI in 
high-risk patients after negative detection on previous or initial biopsies [92]. The 
challenging task with TRUS biopsy is not only to detect PCa but to identify and 
grade cancer for further and more effective management and treatment. Some 
studies proposed that only 28% of TRUS biopsy cases were associated with the 
same original Gleason score compared to the definite Gleason score found after 
radical prostatectomy [93]. The sensitivity of ultrasound to identify prostate 
tumour tissue is insufficient, as it depends on cancer volume rather than cancer 
grade, and is not consistent for detection of cancer in low-risk men with early-
stage PCa [94].  
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1.4 Magnetic Resonance Imaging (MRI) 
Multi-parametric MRI is used to assess multiple organ parameters in the same 
MRI imaging session. The sequences of the mpMRI protocol consist of T2W, 
DWI, and DCE. Optional MR spectroscopy imaging can also be added to the scan 
protocols [95]. MRI provides a detailed and clear anatomical and tissue image of 
the prostate gland structure. It also provides a high intrinsic soft-tissue 
informative assessment such as vascular condition, cellularity, and metabolic 
evaluation.  
Using a surface phased array coil (pelvic-surface coil), the diagnostic accuracy 
performance was reported to be 77% overall with a sensitivity and specificity 
reaching 71% and 74% respectively [96]. The pelvic surface coil produces an 
image showing a respectable detailed anatomical pelvic structure, yet it does not 
establish an accurate diagnostic image for smaller sized organs such as the 
prostate gland, which may result in an adverse low diagnostic outcome [97]. 
The introduction of endo-rectal coil (ERC), which suggested a better images  
increase the diagnostic accuracy and performance. An ERC captures better and 
more detailed gland morphology of the prostate and adjacent tissues, and gives an 
opportunity to maximize the utilization of functional mpMRI sequences [96]. An 
ERC accompanied with 3 Tesla imaging systems are responsible for increasing 
the overall diagnostic accuracy to 97%, sensitivity and specificity 88% and 98% 
respectively [96, 98]. Special care must be taken with the use of ERC to avoid or 
minimize artifacts during imaging, such as caused by air in the rectal bulb. 
Additionally, patient discomfort can cause movement, which leads to 
malpositioning and motions artifacts.  
Clinical MRI imaging is typically performed with two types of magnetic field 
strength fields, either 1.5 or 3 Teslas (1.5T or 3T). Both strengths have been 
recognized by radiologists, however, 3T MRI systems increase the signal to noise 
ratio (SNR) and spatial resolution, resulting in well developed image and more 
enhanced resolution quality  [99]. 
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MRI  should be postponed for 6-8 weeks after a prostate biopsy to avoid any 
haemorrhage artifacts. Prostate haemorrhage is considered as one of the possible 
cancer confounders, mimicking cancer on MRI. The patients are instructed to 
abstain from any sexual activity for 72 hours before the scan to increase seminal 
vesicle volume and improve cancer detection. Patients are also advised to fast at 
least 4 hours and empty their bladder one hour before the MRI scan. Use of 
Scopolamine is sometimes required to reduce bowel movement, decreasing 
patient discomfort and minimizing artifacts [100]. 
MRI allows prostate gland assessment with higher spatial resolution and soft 
tissue contrast compared to any other imaging modalities.  The three most 
relevant MRI sequences in our study were T2-weighted, DCE, and (DWI) 
(Figure 1.14).  
1.4.1 T2-Weighted Imaging (T2W) 
T2W is the main squence used for prostate MR imaging. It is conducted with a 
Fast Spin Echo (FSE), also known as a Turbo spin echo (TSE) sequence with 
multiple spatial planes, enabling a better assessment of the gland volume than 
with other imaging modalities [95]. The T2W sequence creates an image with a 
detailed spatial resolution and soft tissue contrast, enabling full evaluation of the 
zonal anatomy and adjacent tissues, including the urethra, seminal vesicle, 
extracapsular extension, and neurovascular bundles [101]. The high-water tissue 
content is represented in the T2W image with a high signal intensity while fat is 
displayed with a low signal intensity. In the case of presence of prostate cancer, 
water content is diminished significantly leading to a low signal intensity in 
contrast to normal adjacent prostate tissue [102].  
The multi-planer sequence includes the axial plane, which must be combined with 
sagittal and coronal planes. The image generated by the axial sequence typically 
includes the bladder dome superiorly until the perineal area inferiorly, and the 
coxo-femoral joint borders bilaterally. The sagittal plane enables the evaluation of 
the prostate gland posterior surface and its relation to the rectum and the bladder. 
The coronal plane, which is slightly oblique along with the main prostate axis, 
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allows for a better assessment of the transition and peripheral zone, and in 
particular the lateral and anterolateral horns [97].  
The normal peripheral zone appears in the T2W sequence as hyperintense, 
particularly due to the presence of a significant amount of glandular and high-
water content tissue with a clear crescent or horseshoe shape through the mid-
gland section. The peripheral zone is surrounded by a prostate capsule, which 
appears as a thin, full hypointense layer, that circles the whole gland. The prostate 
capsule has a substantial clinical significance, as it is used as a landmark in 
staging PCa [101]. Cancer in the peripheral zone is characterized by an oval or 
nodular shape focus with low-signal intensity. The  sensitivity in detecting PCa in 
T2W reaches more than 90% with Gleason score of 7 and higher, and decreases 
markedly with Gleason score lower than 6 [100]. 
The Central and Transition zones are hard to distinguish when there is no 
evidence of BPH presence. The differentiation  of the central zone could reach 
80% with current MRI systems [103].   
The transition zone consists of less glandular tissue with low water content 
compared to the peripheral zone. The internal gland, which forms from the 
transitional and periurethral zone is categorized by intermediate signal intensity, 
which increases the challenge for detecting cancer in the transitional zone due to 
signal overlapping of tumours and BPH.  The central gland is surrounded by a 
thin hypointense layer isolating it from the peripheral zone [100].   
The transition zone in the presence of nodular hyperplasia shows heterogeneous 
signal intensity depending on the nodules’ consistency. Two types of nodules can 
be found in the transition zone, glandular and stromal nodules. Glandular nodules 
represent the more common type. It appears as a homogeneous high signal 
intensity due to high fluid content with a thin layer of the hypointense capsule.  
The second type is a stromal nodule, which has a homogeneous low-signal 
intensity surrounded by a fine hypo-intense capsule. The stromal nodule is more 
relatively challenging to identify due to its distinct variation [96]. The malignant 
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tissue in TZ appears homogeneous with vague or blurred margins giving an 
erased charcoal sign, lenticular, or water drop shape [104].    
Identifying PCa in the central zone with T2W imaging is quite challenging [105]. 
It appears as a collection of tissue separating the transition zone from the 
peripheral zone on an axial view with low-signal intensity compared to the outer 
region. The central zone tissue is commonly pushed laterally towards the 
peripheral zone by glandular hyperplasia of the transitional zone. The coronal 
view sequence illustrates the central zone as a triangle or tear-drop-shaped 
appearance ranging from seminal vesicle to verumontanum area [105].  
The anterior fibromuscular stroma (AFMS)  is the most anterior structure of the 
gland with a crescent or wedge-shaped appearance. It is characterized by 
homogenous, marked hypointense signal on T2W, which is best seen in an axial 
view sequence. Cancer involvement in AFMS is signified by a high signal 
intensity rounded in shape and external protrusions that affect gland symmetry 
and sometimes prostate capsule continuity in the case of external prostatic 
extension (EPE). Due to its heterogeneous appearance, a normal central zone 
tissue could mimic cancer on T2W and ADC imaging [96, 106].  
The coronal view sequence gives excellent detail of the seminal vesicles, and has 
a variable signal intensity that relies on fluid volume. Aging has an adverse 
physiological effect on fluid volume inside the seminal vesicle leading to a 
decrease in signal intensity. Cancer involvement in the seminal vesicles is 
characterized by thickening of its wall, asymmetric shape appearance, focal or 
diffuse low signal intensity, and enlarged ejaculatory ducts [107-109].  
The sagittal view provides an excellent imaging tool to assess the bladder neck, a 
full length of the prostatic urethra, seminal vesicle and its relationship to the 
rectum and Denonvilliers's fascia. This provides a practical tool for PCa staging. 
Cancer mimickers in T2W images include the central zone, stromal BPH, 
ejaculatory ducts, haemorrhage, and chronic prostatitis. 
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1.4.2 Diffusion-Weighted Image (DWI) and Apparent Diffusion 
Coefficient (ADC) 
The diffusion-weighted image (DWI) sequence is based on Brownian motion of 
water molecules in tissues, which is affected by tissue temperature and by degree 
of cellularity [110]. The diffusion of fluid occurs from a high concentration zone 
to a lower concentration zone, and is controlled by tissue thermal energy and 
cellularity. The DWI sequence provides the ability to assess the micro-
architecture of the imaged tissue [111]. The coefficient “b” is the determining 
factor of the diffusion sequence. The level of sensitivity of water molecules 
weighted diffusion is directly proportioned with “b”.  The “b” coefficient is 
affected by the diffusion parameters, which include distance, intensity, and 
duration between two tissue gradients. Thus, DWI will be more sensitive to 
tissues with a higher diffusion coefficient [96, 101] 
The quantitative assessment of the reconstructed DWI image is used to generate a 
visual map called the Apparent Diffusion Coefficient (ADC). The ADC map, 
expressed in units of 𝑚𝑚2/s, is calculated using the “b” coefficient, which 
represents the degree of water molecules diffusion in the targeted tissue [96]. The 
ADC map establishes an estimated average value of each voxel in the imaged 
region and is displayed as an opposite contrast to the captured DWI image. This 
process assists in eliminating the T2 shine-through effect as ADC measures the 
degree of diffusion independent from the T2 shine influence. [95, 112]. 
Water diffusion in healthy prostate tissue is captured as a low signal intensity due 
to low or regular cellularity due to free water diffusion. The image is depicted as a 
hyperintense value on ADC. In contrast, cancer tissue is associated with crowded 
small glands, and cells with a larger nucleus to cytoplasm ratio, a limited amount 
of stroma between glands, reduced extracellular space, and abnormal 
parenchymal tissue structure. These changes diminish water molecule diffusion in 
tissues, and result in a high signal intensity on DWI, which is converted to a 
hypointense value on an ADC image [95, 101]. DWI and ADC images in addition 
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to T2W could provide an extra quantitative assessment of prostate tumour 
behavior and aggressiveness [113]. 
1.4.3 Dynamic Contrast-Enhanced (DCE) 
PCa is found to be associated with a new vascular formation with high vascular 
density and permeability in a process called neoangiogenesis. This blood supply 
provides the necessary nutrients to tumour cells [114]. DCE-MRI is a functional 
imaging method with the ability to assess the vascular supply and microvascular 
structure of the tissue in a given zone by capturing the tissue enhancement after 
intravenous administration of a contrast agent. The DCE imaging procedure takes 
approximately 5-10 minutes to complete. A fast T1W sequence is required to 
acquier multiple serial images within a short time interval before and after 
contrast injection. T1W images will establish a baseline evaluation of the tissue 
during contrast injections to distinguish the contrast influx to the prostate gland, 
and post-injection, to estimate the uptake and washout time of the contrast. These 
multiple scans provide images of the prostate tissue perfusion for assessment 
[115]. The DCE images are obtained with high temporal resolution and a 3D 
acquisition mode. 
The DCE image is generated by injecting rapidly a contrast agent of low-
molecular-weight gadolinium chelate  at a rate of 2-4mL/S followed by a saline 
flush [101]. The contrast agent molecules will diffuse into the extracellular 
extravascular space (interstitial space), termed as the leakage space. Abnormal 
neovascularization and reconstruction, which accompany the prostate tumour, will 
have a stronger vascular leakage, resulting in the prostate tumour having a 
quicker, more intense contrast enhancement compares to the normal adjacent 
tissues followed by rapid washout before surrounding tissue [96].  
There are three methods available for assessing DCE images, qualitative, semi-
quantitative and quantitative. The qualitative assessment approach is based on the 
visual analysis of the potential cancer area with observation of the rapid regional 
significant enhancement and early washout of the contrast agent compared to the 
adjacent tissue. This method is subject to inter-observer experience and variability 
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with the least standardization capability. BPH, transitional zone, and 
inflammation could be responsible for relatively high enhanced image on DCE 
sequence and quicker washout compared to the rest of the gland tissue, but not to 
the same extent as PCa [102, 116]. 
The semi-quantitative approach utilizes the time and intensity curve in addition to 
the same principle used in qualitative assessment including the time for 
enhancement and washout. The time/intensity curve estimates the time to obtain 
maximum peak enhancement, the slope of the curve, wash-in or wash-out times. 
Three types of time/signal intensity curves are commonly generated with a 
software aid. The persistent type 1 curve shows a clear evidence of the constant 
progress of enhancement after the initial peak. Type 2 curve, which is named a 
plateau, shows a curve that flattens after the initial peak. Type 3 curve is named 
the decline, and is characterized by rapid decline of the curve after the initial peak 
[117, 118]. Prostate tumours are more likely to be associated with a type 3 curve, 
but can produce type 1 and type 2 curves to a lesser extent [119].  
Quantitative DCE image assessment utilizes multifaceted methods including 
pharmacokinetic  parameters such as the volume transfer constant (𝐾𝑡𝑟𝑎𝑛𝑠), which 
evaluates the contrast agent influx from blood vessels and capillaries into the 
interstitial space, which is extracelluler and extravaculer. (𝐾𝑡𝑟𝑎𝑛𝑠) is influenced 
by blood flow, vascular permeability  and surface area [120]. The reverse reflux 
rate of contrast agent from the interstitial space back to the vascular stream is 
(𝐾𝑒𝑝), and (𝑉𝑒) represents the extracellular, extravascular volume fraction and are 
related thus: 𝐾𝑒𝑝= 𝐾
𝑡𝑟𝑎𝑛𝑠/𝑉𝑒 [117]. Many software applications have been 
developed to generate more accurate and quantitative DCE map parameters to be 
used in developing more standardized assessment guidelines in the evaluation of 
PCa from DCE images. Prostate cancer will produce an increase in 𝐾𝑡𝑟𝑎𝑛𝑠 and 
𝐾𝑒𝑝. The current method of choice is the quantitative assessment of DCE images, 
despite its high complexity compared to semiquantitive assessment [117].    
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(Figure 1.14) In-vivo prostate multiparametric MRI and its corresponding 
histopathology digital image. (A) Axial T2W image with an area of 
hypointensity on the right posterolateral aspect of prostate gland (light blue) 
contour. (B) Dynamic contrast-enhanced image. (C) ADC map with hypointensity 
in the same region. (D) Histopathology digital image for the whole-mount 
prostate section with adenocarcinoma features in same region (brown) contour. 
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(E) 10X image of the affected area showing Gleason grade 4 (G4) 
adenocarcinoma. (F) High power view for the affected area (rectangular) with a 
G4 cribriform pattern. 
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1.5 Prostate Imaging Report and Data System (PI-
RADS) 
The emergence of MRI as a useful tool in detecting and localizing prostate cancer 
was accompanied by an initial lack of standardization in interpreting of this 
imaging data between radiologists with similar earlier challenges faced with 
breast mammogram. Thus, there was an urgent need to develop an assessment 
approach to be widely adopted by experts to improve the quality of reporting, 
create a better standardization and reduce inter-observer variability.    
Multiple assessment methods have been introduced to evaluate prostate mpMRI. 
One of the preliminary methods was assessing the suspected lesion on a binary 
scale whether it is positive or negative for malignancy [121]. Based on the 
number of sequences marked as positive, the suspected lesions were asigned a 
score of low, intermediate and high. Despite the simplicity, this approach was not 
popular due to the inability of addressing the variability of degree of abnormality 
observed in the MR image sequences [122].  
Recently, the Prostate Image Report and Data System (PI-RADS) has gained 
international popularity since it was introduced by the European Society of 
Urogenital Radiology, followed by publishing a guideline in 2012 [123]. They 
aimed to develop a clinical guideline that focuses on the three optimal diagnostic 
technique for detecting, staging, node and bone involvement.  
To assess prostate mpMRI images using a PI-RADS score, prostate images should 
be acquired using a high-field scanner with 1.5 Tesla (1.5T) as a minimum field 
strength accompanied by endo-rectal and body phase array coils to yield a high 
signal to noise ratio. An endo-rectal coil could be optional with field strength of 3 
Tesla [124]. 
The T2W image using turbo-spin-echo (TSE) is the main method for prostate MR 
imaging as it provides a highly detailed image of the prostate anatomy and 
surrounding tissues with visually recognizable zonal morphology. T2W images 
are acquired with axial, sagittal and/or coronal sequences [124], and a T1W image 
is also highly suggested to rule out any intraprostatic haemorrhage from a prior 
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biopsy or inflammatory reactions. The T1W image could also be helpful in 
assessing parailiac and regional lymph nodes enlargement, suggesting a metastatic 
disease [124].  
The PI-RADS classification of T2W is based on zonal anatomy. Two separate 
schemes are endorsed for different zonal anatomy as the contrast varies between 
peripheral zone and central gland (Table 1.2-1.3). Also, any involvement of the 
bladder neck, seminal vesicles invasion or extra-prostatic extension must be noted 
[125, 126].  
The PI-RADS interpretation of DWI is based on images acquried with a high b-
value (b≥800s/mm2) with corresponding apparent diffusion coefficient map. Each 
lesion is assessed with a score 1-5 according to signal intensity and localization 
[127].  
Any increased signal in DWI aquired with  a high b-value not accompanied by a 
focally reduced the signal in the ADC maps is assigned a Score of 1. Diffuse 
hyperintense signals on DWI with a reduced signal on a corresponding ADC map 
is assigned a score of 2 (lesion cannot be delineated). Score 3 is assigned to a 
diffuse asymmetrical or unilateral high intense signal on the high-b-value image, 
which is accompanied by a decreased signal on a corresponding ADC image. 
Focal lesions that are isointense on DWI with a high b-value and a signal 
reduction on a corresponding ADC map are assigned a score of 4. The focal 
significant reduction on an ADC map with a focal hyperintense signal in a 
corresponding DWI image with a high b-value (b≥800s/mm2) is assigned a score 
of 5 (Table 1.4) [123, 124]. 
The PI-RADS is used to assess each mpMRI image individually with a score 
range from 1 to 5. The assessment followed by an overall score varies from 1 to 5.  
Each area and suspected lesion in an image generated by the different sequences 
should be evaluated separately with a scoring between 1 and 5. The total overall 
rating is then calculated based on a number of lesions, locations and each lesion 
score with the possibility of the presence of extraprostatic extensions. An overall 
score ranging between 1 and 5 characterizes the probability of the presence of a 
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clinically significant tumour. Transitional zone assessment must be performed 
separately from the peripheral zone [122, 123].  The PI-RADS assessment must 
include the seminal vesicles, prostate capsular involvement or any sign of 
potential or compact evidence of extraprostatic extension [123].  
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         Score  Criteria 
1 Uniform high signal intensity (SI) 
2 Linear, wedge shaped or geographic areas of lower SI, 
not well demarcated 
3 Intermediate appearances not in categories 1-2 and 4-
5 
4 Discrete, homogeneous low signal focus/mass 
confined to the prostate 
5 Discrete, homogeneous, low SI focus with EPE, 
invasive behaviour or mass effect on capsule (e.g. 
bulging) 
(Table 1.2) PI-RADS scoring system classification criteria for T2W image 
assessment for the peripheral zone [123] 
 
 
 
 
 
 
 
 
(Table 1.3) PI-RADS scoring system classification criteria for T2W image 
assessment for the Transition zone [123] 
 
 
 
         Score  Criteria 
1 Heterogeneous TZ adenoma with well defined margins 
(organised chaos) 
2 Areas of more homogeneous low SI, well defined 
margin, originate from TZ/BPH 
3 Intermediate appearances not in categories 1-2 and 4-5 
4 Areas of more homogeneous low SI, ill defined (erased 
charcoal) 
5 Same as 4, involving the AFS or anterior horn of PZ, 
lenticular or water drop shaped 
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(Table 1.4) PI-RADS scoring system classification criteria for Diffusion 
Weighted Imaging (DWI) image assessment [123] 
 
 
         Score  Criteria 
1 No reduction in ADC compared with normal glandular 
tissue. No increase in SI or any high b-value image 
(≥b800) 
2 Diffuse, hyper SI on ≥b800 image with low ADC. No 
focality however, linear, triangular or geographical 
features are acceptable 
3 Intermediate appearances not in categories 1-2 and 4-5 
4 Focal area(s) of reduced ADC but iso-intense SI on high 
b-value images (≥b800) 
5 Focal area/mass of hyper SI high b-value images (≥b800) 
with reduced ADC 
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(Figure 1.15) Twenty-seven regions of interest for the standardized PI-RADs 
scheme [128],  a: anterior, as: anterior stroma, p: posterior, R: right, L: left. SV: 
seminal vesicles. 
 
PI-RADS 
Score  
Interpretation 
1 Benign, highly unlikely for malignancy  
2 Most probably benign or unlikely for 
malignancy  
3 Intermediate or equivocally  
4 Likely or probably malignant 
5 Highly suspicious of malignant  
(Table 1.5) Interpretation of PI-RADS scoring assessment [124, 128] 
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1.6 Rationale 
Our study aims to gain a better understanding of non-cancerous pathological 
lesions in prostate gland and their relationship to mpMRI signal that could be 
mistaken as a potential cancer signal on MRI.  
This may help increase cancer detection accuracy and reduced false positive 
detection of prostate cancer. 
1.7 Hypothesis 
Atrophy, PIN, and BPH are the main non-cancerous pathology that could mimic 
cancer like signals on mpMR images due to their morphological similarity with 
adenocarcinoma. 
1.8 Specific Aim 
The objective of the study is to test and examine non-cancerous pathology lesions 
and their subtypes that could raise a false positive cancer like signals on mpMRI.  
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Chapter 2 
2 Materials and Methods 
This study was approved by the Human Subject Research Ethics Board London 
Health Sciences Center, (LHSC), and University of Western Ontario, London, 
Canada). A written informed consent was obtained from each patient before a 
non-clinical standard set of in vivo prostate gland scan. Images were taken two to 
three weeks in advance of surgery. 
2.1 Materials 
A total of 19 patient were enrolled in the study. Patients who participate in the 
study have been previously diagnosed with prostate cancer through prostate 
biopsy. Prior to prostatectomy, a multi-modality set of images including an in vivo 
multiparametric Magnetic Resonance images (mpMRI) were acquired from each 
participant using a 3 Tesla MRI scanner (GE Discovery MR750, GE Healthcare, 
Waukesha, WI) [129] with the use of an endorectal coil (Prostate eCoil; Medrad, 
Warrendale, PA) surrounded by barium sulfate suspension in a sheath [129]. The 
mpMRI included high-resolution T2W images for diagnostic assessment, also to 
allow registration to other modalities, Dynamic Contrast Enhanced (DCE) and 
Apparent Diffusion Coefficient (ADC) images [130]. The in vivo mpMRI images 
were obtained after the biopsy and before surgery. The mpMR Imaging was 
performed 19 weeks (± 8 weeks) following the biopsy. This period was to allow 
the prostate gland a recovery period to avoid haemorrhage interference with the 
analysis of the images. 
A strict patient inclusion and exclusion criteria allowed for the collections of the 
radical prostatectomy specimens from 19 cases. Patient inclusion criteria were as 
follows: the patient must be at least eighteen years of age and have a confirmed 
clinical diagnosis of PCa histologically, clinical classifications of the tumour 
grade between T1 and T2 by trans-rectal ultrasound (TRUS) guided biopsy, and 
radical prostatectomy as the choice of treatment. Patient Exclusion criteria were: 
any use of 5-alpha reductase inhibitors in the past 6 months prior to study 
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enrolment, any prior therapy for PCa, any contraindications to perform and 
acquire the preoperative set of MR imaging with contrast as renal functions 
impairments, sickle cell disease or any other type of anemia, and allergy to the 
contrast agents or any source of artifact in the pelvis (e.g. hip prosthesis).    
The T2W imaging was performed with a two-dimensional (2D) and three-
dimensional (3D) fast spin-echo sequence (repetition time msec/echo time 
msec,6050/163; bandwidth, ±31.25 kHz; two signals acquired; field of view, 14 
cm; section thickness 2.2 mm; matrix -384 × 256; 40 slices) and (2000/148.5; 
bandwidth, ± 125 kHz; one signal acquired; field of view, 14cm; slice thickness, 
1.4 mm; matrix, 320 × 192; 84 slices) for 2D and 3D T2W respectively. The T1 
weighted images were acquired with the 3D spoiled gradient-recalled echo 
(5.6/2.1; bandwidth, ±31.25 kHz; two signals acquired; field of view, 14 cm; 
section thickness, 2.8mm; matrix, 256 ×192; 42 sections; flip angle, 15°;7 
volumes acquired at 90 sec/volume) [130]. The T1W imaging was performed 
after administration of gadopentetate dimeglimine (Magnevist; Bayer Healthcare 
Pharmaceutical, West Haven, Conn) intravenously [130]. The dose of 
gadopentetate dimeglimine was 0.1 mmol per kilogram body weight with 
injection rate of 4 ml/sec followed by 20ml of saline flush. The radical 
prostatectomy followed in vivo imaging. The resected prostate specimens were 
fixed in formalin for 72 hours before fiducial insertion, ex vivo MR imaging, and 
histopathology processing (Figure 2.1). 
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(Figure 2.1) Overview of the steps in our method used in prostate specimen 
processing.  
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2.2 Methods 
2.2.1 Fiducials Processing 
Before obtaining ex vivo prostate MR images, two sets of 10 standard shape 
fiducials markings were applied to the prostate gland. The aim of this non-
anatomical markings was for them to be visible in the ex vivo MR and digital 
histology images. The fiducials were required to be able to endure the heat and 
the tough chemical treatment through gland grossing and histology processing 
without any distortions or damage to the tissue. In contrast, these fiducials should 
not have any impact on pathologists’ assessment. This was ensured as any 
alteration to pathology assessment will have a significant impact on post-surgery 
patient care and management. 
The internal fiducial markers consisted of three cotton threads soaked in blue dye 
designed for tissue marking (Triangle Biomedical Sciences, Durham, NC) and 
1:40 gadopentetate dimeglumine, which enabled visibility and identifications of 
the fiducials on T1 weighted MRI [131]. The internal fiducials applications were 
completed with the assistance of 18G cannula and stylet with a Quincke-type 
point (Figure 2.2). The cannula with a stylet was designed to perform a clear 
tissue separation to avoid any tissue damage during the insertion processes. The 
cannula and stylet were inserted into the prostate gland from the base and exit at 
the apex with an optimal target to be within one centimeter posteriorly to the 
anterior urethral opening.  Strict measurements were applied with caution to keep 
the cannulas at a fair distance from the urethral structural and openings to avoid 
any clinical assessment alteration or aggressive treatment methods for follow up 
management due to possible higher tumour staging diagnosis. Following the 
insertion of total three 18G cannulas and style, two on the right prostate lobe and 
one on the left lobe, the stylets were then removed, and a fair length cotton thread 
was inserted through each cannula. The free part of threads were soaked in blue 
dye and gadolinium.  Following the cotton thread insertion with the blue dye,  the 
cannula and cotton thread were pulled together outside the prostate tissue leaving 
the free soaked thread part with the blue dye and Magnevist within the prostate 
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tissue (Figure 2.3). The applied dye tissue marking enabled localization during 
digital histopathology analysis, and the gadolinium allowed localization in the ex 
vivo MRI. The cotton threads were removed after whole gland MR imaging and 
before specimen slicing to avoid any tissue disruptions during specimen slicing 
[132]. 
Cylinder-shaped surface-mount fiducials were extracted from a formalin fixed 
lamb or pig kidney cortex via 16G biopsy needle (the same model used in a breast 
biopsy) (Figure 2.4). After successful extraction, they were completely immersed 
in 1:40 gadopentetate dimeglumine and 10% buffer formalin for a minimum of at 
least 20 minutes to ensure the completion of infusions. The fiducials were firmly 
fixed to the prostate surface using 411 Loctite ethyl cyanoacrylate adhesives 
(Loctite 411; Henkel, Dusseldorf, Germany) (Figure 2.5). Loctite 411 does not 
interfere or generate any tissue damage during the cutting processes.  
Furthermore, Loctite 411 is sufficiently tough enough to survive the heat and 
chemicals through histology processing, preventing the external fiducial from 
deteriorating or disruption during the rough processing methods.  The following 
step includes three fiducials applied on the posterior surface with one fiducial on 
each side with a 45° angle, and the remaining fiducial was applied centrally.  On 
the anterior surface, three parallel fiducials were attached with two on the left side 
and one on the right.  A fourth fiducial was placed diagonally from the right 
anterior to left posterior apex to base.  Thus, a total of seven fiducials were 
mounted on the surface of the prostate [130-133]. 
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(Figure 2.2) Prostate gland with three 18G cannulas with inserted threads 
after removing the style. (Rt) right side, (Lt) left side (a) 2 threads on the right 
side and (b) 1 on the left side of the prostate gland.   
 
(Figure 2.3) Prostate gland after threads soaking in Magnevist & dye, 
followed by removing 18G cannula leaving threads inside the glands. 
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(Figure 2.4) The external fiducials obtained from a pig kidney by using breast 
biopsy needle 
  
(Figure 2.5) The anterior and posterior surface of prostate gland post-
fiducials application. (A) The anterior surface of prostate gland post fiducials 
application (pig Kidney) using 411 Loctite ethyl cyanoacrylate adhesives. Total of 
4 fiducials, (a) 2 fiducials on the left side, (b) 1 placed diagonally, and (c) 1 on the 
right side. (B) Prostate gland posterior surface with a total of three fiducials (pig 
kidney) applied using 411 Loctite ethyl cyanoacrylate adhesives.  
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(Figure 2.6) Internal and external fiducial marking in formalin block and 
histopathology image. (A) Image of whole-mount prostate formalin blocks 
surrounded by the remnant of agar after prostate gland slicing and its 
corresponding (H&E) digital histopathology image (B).  A total of 10 fiducial 
markings are clearly visible; 3 internal (black squares) with 2 on the right side and 
one on the left. A total of 7 surface mount fiducials (white arrows on formalin 
block and deep blue arrows on digital histopathology image), 4 on the anterior 
surface and 3 on the posterior. 
 
  
(Figure 2.7) High power digital histopathology images showing 3 visible 
inked internal fiducials marking (3 black squares on Fig: 2.6, B) with deep blue 
ink in 3 internal fiducial markings which were used as landmarks for prostate 
image reconstruction and registrations. 
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2.2.2 Ex-vivo MR Imaging 
The ex vivo MR imaging was performed following the placement of fiducials 
marking. The whole gland was placed and fixed inside in a large glass syringe to 
prevent any movement during the MR scan. The glass syringe was filled with 
Christo-Lube MCG 1046 (Lubrication Technology, Franklin Furnace, OH). The 
Christo-lube is invisible in MR images, which gives zero signals to the 
surrounding regions of the gland. This provides a black background in the image 
and minimizes magnetic boundary artifacts at the prostate gland border. The MR 
images were acquired by an MR750 system (GE Healthcare, Waukesha, WI), 
using a carotid coil instead on endorectal coil in in-vivo MRI scan,  T2W (3D fast 
spin echo; TR/TE:2000/148.5ms; bandwidth, ±125kHz; three signals acquired; 
field of view, 14 cm; slice thickness, 0.4mm; matrix 320×192; 160 sections; 25 
minutes), and T1 weighted signal (3D spoiled gradient-recalled echo; TR/TE: 
6.5/2.5ms; bandwidth, ±31.25 KHz; eight signals acquired; field of view, 14 cm; 
section thickness, 0.4 cm; matrix 256×192; slice; flip angle, 15°; 25 minutes) 
protocols [129, 132]. 
2.2.3 Specimens Slicing, Histopathology Processing, and Digital 
Contouring 
This process was initiated after the removal of the prostate apex.  The aim is to 
remove the prostate apex including the entire anterior urethral opening with at 
least 1 cm in thickness. The pathologist determined the plain of the first cut by 
visual assessment.  Three pins were inserted, which were used for surface 
orientations during surface cuts using slotted forceps (ProCut; Milestone Srl, 
Sorisole, Italy) with design adjustments to avoid any lateral motions between the 
upper and lower forceps plates during cutting processing  [131, 132]. 
Following the apex cut, the specimen was positioned in a square box with the cut 
surface facing the bottom of the box.  The box was filled with liquid agar and 
cooled to 4°C. The whole block was sliced with a rotator blade cutter (GC-9 
Slicer) measuring 4.4 mm thickness from the anterior cut aspect (Globe Food 
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Equipment, Dayton, Ohio) [131]. This thickness enabled simple registrations with 
MRI images since they were obtained with a 2.2 mm image slice thickness. The 
4.4 mm histological thickness also resisted fragmentation or tissue rolling during 
handling and histology possessing. An average of three to five whole-mount 
sections per specimen were completed depending on prostate volume and shape. 
The clinical histopathology processing protocols followed the base cutting, which 
included whole mount paraffin block, microtome cutting at 4 µm thick sections 
from each whole-mount block and staining with hematoxylin and eosin stain. The 
slides were then digitally magnified at 20X (0.5µm/pixel) using the brightfield 
slide scanner (ScanScope GL; Aperio Technology, Vista, CA, USA). Digital 
histopathology images were contoured with a color-coded scheme to identify 
various types of Gleason grades and scores as well as other non-cancerous 
abnormalities such as PIN and Atrophy (Table 3.1). The contouring was 
completed with the use of Cintiq 22-inch HD widescreen computer monitor, 
which included an enabling pen for fine drawing (Wacom Co, Japan) and image 
scope software (Aperio Technology, Vista, CA, USA) (Fig 2.8). The image 
contouring process was done under the supervision of two genitourinary 
pathologists, which their approval is required before submission to allow for the 
next step of registrations to be completed.  
 
 
 
 
 
 
 
 
64 
 
 
 
 G3  G4+3  PIN 
 G4  G4+5  EPE 
 G5  G5+4  Positive Margin  
 G3+4  G5+3  Atrophy 
(Table 2.1) The color coding scheme used for contouring cancer and non-
cancerous lesions on digital histopathology images. (G3) Gleason grade 3, (G4) 
Gleason grade 4, (G5) Gleason grade 5. For the areas, which included more than 
Gleason grade with difficulty to contour separately. Thus, we combined the two 
or more grades together, with respect to dominant grade to be called first.  For 
example, the G3+4 contour present area of two great complexes enough to 
separate them, with the G3 is the dominant grade in this area. PIN: Prostatic 
Intraepithelial Neoplasia, EPE: Extra-Prostatic Extension. 
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(Figure 2.8) Histopathology digital images for a whole-mount prostate section 
showing several contours with there color-coded scheme. (A) Prostate whole-
mount histopathology image with color-coded contours for various types of 
cancer grade and non-cancerous abnormality. (B) 10X power zoom showing 
section with area contoured with (G3) Brown-Gleason grade 3, (G3+4) Green-
Gleason grade 3+4, (EPE) cyan-Extra-Prostatic Extension. (C) reveals a high-
power zoom 20X with G3, G3+4, and EPE. 
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Before full registrations, the in vivo mpMR images were assessed and contoured 
independently by four radiology observers. These observers had various levels 
and years of experience in prostate cancer assessment and diagnosis with mpMR 
imaging. The years of experience varied from five and six years with observer A 
and B respectively, to two and half years with observer C and D. These observers 
were aware that all patients had a biopsy confirmed PCa. However, they had no 
previous exposure to the histopathology diagnosis reports or evaluation for each 
individual case. They contoured unregistered T2W, DCE, and ADC MR images 
sequences separately using Version 1 of the Prostate Imaging Reporting Data 
System (PI-RADS) score system. The observers delineate lesions with a score 
from three to five: equivocally (3), likely (4) and very likely (5) to be a malignant 
tumour area.  In this study, we only considered the same areas outlined by the 
radiology observers in the three-consecutive unregistered sequence of mpMRI, 
T2W, DCE and ADC. The PI-RADS score used in this study is the overall 
assessment score for each lesion in the three-previous consecutive sequence of 
mpMRI. 
2.2.4 Registration 
Initial registration was performed using the 3D Slicer viewing software between 
digital histopathology images and 3D ex vivo MR images with the aid of applied 
fiducials markings [132]. An interactive digital technique was developed in our 
lab for deformable registration of 3D ex vivo MRI and in vivo mpMRI to high 
resolution 3D in vivo T2W MR images with histopathology [133, 134]. Using a 
rigid method of registration and the anatomical homolog landmarks (e.g., Urethra, 
Verumontanum, cystic atrophy spaces, benign prostatic hyperplasia, 
calcifications) the registration error was ≤ 2 mm on average. This interactive 
digital technique allowed navigating simultaneously between the mpMRI 
sequences (T2W, DCE, and ADC) and the contoured histopathology. To avoid 
any confusion or registration errors, we excluded any false positive MRI contours 
adjacent to PCa region on the histopathology digital images. 
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Chapter 3 
3 Results 
3.1  Analysis of MRI Contoured Areas 
(Figures 3.1-3.4) show examples of contoured mpMRI images by the four 
radiology observers and the corresponding histopathology images. These four 
figures illustrate four different patient cases of the 19 cases analyzed in this study. 
 
(Figure 3.1) True Positive mpMRI contour correlated to Gleason grade 3 
adenocarcinoma on histopathology image. (A) Histopathology image showing 
a contoured area (gray arrow) for Gleason grade 3. (B) True positive areas on 
T2W MRI image contoured by the 4 observers, (C) contoured on DCE MRI 
image, and (D) contoured on ADC map and their corresponding area on histology 
with Gleason grade 3, and Gleason scores 6. 
A B C D 
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(Figure 3.2) False Positive mpMRI contour correlated to the area with 
atrophic glands. (A) A false positive area on T2W MRI image contoured by one 
observer (gray arrows). (B) Contoured on DCE MRI image, and (C) contoured on 
ADC map. The corresponding area on histology shows atrophic glands change on 
Histopathology image (D). 
 
(Figure 3.3) False Positive mpMRI contour correlated to the area with BPH. 
(A) A false positive area on T2W MRI image contoured by one observer (gray 
arrows). (B) Contoured on DCE MRI image, and (C) contoured on ADC map. 
Their corresponding area on histology displays BPH on Histopathology image 
(D). 
A B C 
D 
A B C D 
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(Figure 3.4) False Positive mpMRI contour correlated to the area with 
prostatic intraepithelial neoplasia (PIN). (A) A False positive area on T2W 
MRI image contoured by one observer (gray arrows). (B) Contoured on DCE 
MRI image, and (C) contoured on ADC map. The corresponding area on 
histology shows PIN on Histopathology image (D). 
The graphs in (Figure 3.5-3.6) demonstrate the analysis results of the 37 MRI 
contoured areas. After corresponding these radiology contoured areas to the 
corresponding histological regions. This analysis shows the number of each non-
cancerous lesion (PIN, Atrophy, BPH, normal histology) and their PI-RADS 
score assessed on MRI.  
The first radiology observer (A) had six years of experience in prostate MRI 
imaging assessment and PCa diagnosis. This observer contoured seven suspicious 
lesions in MRI, which were identified on histology to be false positive areas. 
After corresponding these contoured MRI areas, histology images revealed three 
lesions of PIN with a PI-RADS score 4. Of the other three atrophic areas, two 
were given a PI-RADS score 3 and one a PI-RADS score 5 on the contoured 
unregistered MRI images. 
The second radiology observer (B) had five years of experience in prostate MRI 
assessment.  This observer contoured a total of fourteen areas in the MRI images, 
which were a false positive.  Histology images revealed that four of these areas 
A B C D 
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were PIN, two lesions were marked as PI-RADS score 3, another area was labeled 
as PI-RADS score 4 and one as PI-RADS score 5. Histology images showed that 
atrophy was represented in six MRI susceptible lesions. Three areas were assessed 
as PI-RADS score 3, and the other three were given PI-RADS score 4.  BPH was 
found in three areas, two of them were PI-RADS score 3, and one was a PI-RADS 
score 4. There was one area assessed as a PI-RADS score 3, which the histology 
revealed to be a non-pathological central zone structure.  
The third radiology observer (C) had two and a half years of experience in 
prostate MRI assessment. This observer contoured a total of seven areas on MRI, 
which were false positive areas. Corresponding histology images of contoured 
MRI areas revealed that five areas were PIN and two were atrophic regions. Of 
these five areas, two had a PI-RADs score 3, and two had PI-RADs score 4, and 
one area with PI-RADS score 5 assessments. The PI-RADs score for the two 
atrophic areas were assessed as score 4 and 5. 
The fourth radiology observer (D) also had two and a half years of experience in 
prostate MRI imaging. This individual contoured a total of nine regions, which 
were false positive areas. Corresponding histology images to MRI contoured 
areas with PI-RADS score 3 and above revealed that four areas were PIN. Of 
these four areas with PIN, one had a PI-RADS score 3, two had a score of 4, and 
one area had a score 5. Two areas with PI-RADS score 3 and 4 were regions of 
atrophy. BPH was in one contoured area with PI-RADS score 4, and two areas 
with normal structure were contoured on MRI as PI-RADS score 4 and 5.   
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Figure 3.5. Histogram demonstrate the total PI-RADS scores assessment 
performed by the 4 radiology observers and their corresponding histology 
findings.  Histogram demonstrate the total PI-RADS score assessment contoured 
by four radiology observers on three functional MRI image sequences (T2W, 
DCE, ADC) and their corresponding non-cancerous lesions on digital 
histopathology images (n=19). 
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Figure 3.6. Histograms of the frequency of the PI-RADs score of contoured areas on 
mpMRI by each observer separated by the histologically identified non-cancerous 
lesions on HDI.  
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3.2 Analysis of Histology Areas Corresponding to 
MRI 
(Table 3.1) shows a summary of the analysis of the histology images, which 
corresponded to MRI contoured areas. The graphs in (Figure 3.7) display the 
frequency of each non-cancerous lesions (PIN, Atrophy, BPH, normal histology) 
and their PI-RADS score assessment. 
The 23 digital histology images showed that PIN was found in 10 areas.  With 8 
areas demonstrating solitary PIN and 2 areas with PIN admixed with other non-
cancerous lesions. Of the 8 areas with a solitary PIN, 2 areas were found with a 
flat pattern, 2 areas with a papillary pattern, 2 with tufting and 1 with a cribriform 
pattern. There are 2 areas found with 2 patterns mixed between flat and tufting 
and 1 area mixed between papillary and cribriform. The remaining 2 areas 
admixed with other non-cancerous lesions were found to be a flat pattern, 
admixed with  simple atrophy. The other area was a flat and tufting pattern along 
with Post-Atrophic Hyperplasia (PAH). 
Analysis of these PIN areas, which were contoured 16 times in MRI by the four 
radiology observers, revealed that five contours were assessed as PI-RADs score 
3, eight contours as PI-RADs score 4, and three contours as PI-RADS score 5.  
Of the 23 corresponding histology areas to MRI, atrophy was present in seven 
areas. Of these atrophic areas, 3 areas were found to be with post-atrophic 
hyperplasia. One area had simple atrophy, and another was mixed between simple 
and cystic atrophic subtypes. Two atrophic areas were admixed with a PIN, one 
area displayed simple atrophy and another displayed simple and PAH. These 
atrophic areas were contoured on MRI thirteen times by the four radiology 
observers. Six contours were assessed as PI-RADS score 3, five contours were 
assessed as PI-RADS score 4 and two contours with PI-RADS score 5.  
BPH was found to be represented in five areas, which consisted of glandular and 
stromal components. An epithelial component was represented in 60% or higher 
in these nodules. On the corresponding MR images, the radiology observers 
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contoured three of these five areas as PI-RADs score 3 and two areas as PI-RADS 
score 4. 
Normal prostate tissue was present in three areas on the digital histology images, 
which corresponded to contoured regions on MRI as potential cancerous lesions. 
One area was in the anterior fibromuscular stroma region, and the other two were 
in the central zone structure.  
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Figure 3.7. Histograms of the frequency of the PI-RADs score for the 
individual non-cancerous lesions. 
 
Sum of 
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areas 
PIN Mixed 
between 
PIN & 
atrophy 
   Atrophy BPH Normal 
structures 
23 8 2 5 5 3 
Table 3.1. Summary of the total number corresponding digital histology image areas 
to contoured MRI areas delineated by four Radiology observers. 
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3.3  Analysis of PI-RADS Score Corresponding to 
Histopathology Digital Images  
(Figures 3.7 - 3.9) show the results of the analysis of each PI-RADS scored area 
and their frequency of non-cancerous lesion as contoured by the four observers. 
PI-RADS score 3 areas were contoured by the four observers fifteen times. The 
corresponding histopathology images revealed that PIN, atrophy, BPH and a 
normal structure were represented in 5, 6, 3 and 1 areas respectively.   
A PI-RADS score 4 was evaluated and contoured by the four observers on MRI in 
sixteen areas. The digital histopathology images, which corresponded to MRI 
contoured areas revealed that PIN, Atrophy, BPH and normal structure were 
represented in 8, 5, 2 and 1 areas respectively.  
A PI-RADS score 5 was assessed six times on MRI by the four radiology 
observers. The corresponding areas of these MRI contoured areas to 
histopathology digital images demonstrated PIN, Atrophy, BPH and normal 
structure presented in 3, 2, 0 and 1 respectively. 
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Figure 3.8. Histogram characterizing the total frequency of each PI-RADS 
score assessment provided by four radiology observers and their 
corresponding non-cancerous lesions on digital histopathology images (n=19) 
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Figure 3.9. Histograms of the frequency of total assessment of PI-RADS 
score 3 for each of the four observers. (A) The graph shows the total number of 
PI-RADS score 3 with the corresponding histology of non-cancerous structures on 
digital image slides (n=19). (B) The graph shows the total number of PI-RADS 
score 3 assessment by the four observers and their corresponding areas of non-
cancerous structures on digital image slides (n=19). 
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Figure 3.10. Histograms of the frequency of total assessment of PI-RADS 
score 4 for each of the four observers. (A) The graph shows the total number of 
PI-RADS score 4 with the corresponding histology of non-cancerous structures on 
digital image slides (n=19). (B) The graph shows the total number of PI-RADS 
score 4 assessment by the four observers and the corresponding areas of non-
cancerous structures on digital image slides (n=19). 
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Figure 3.11. Histograms of the frequency of total assessment of PI-RADS 
score 5 for each of the four observers. (A) The graph shows the total number of 
PI-RADS score 5 with the corresponding histology of non-cancerous structures on 
digital image slides (n=19). (B) The graph shows the total number of PI-RADS 
score 5 assessment by the four observers and the corresponding areas of non-
cancerous structures on digital image slides (n=19). 
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The assessment of the 19 mpMRI prostate surgery cases illustrated that 23 areas 
on histopathology digital slides corresponded with non-cancerous lesions. These 
areas were assessed by the four radiology observers as a potential PCa on the 
corresponding areas in the MRI images.  Each of the 23 histopathology areas was 
individually examined, verified and contoured in the MRI images by at least one 
or more observers. These areas were contoured a total of 37 times by the 
observers. Multiple areas were contoured by more than a single radiology 
observer. (Table 3.2) displays the total number of times that the radiology 
observers contoured areas, which were found to be non-cancerous when the 
corresponding areas were examined in the histopathology slides.  
Examination of the MRI images, which corresponded to the 23 digital 
histopathology images showed that 16 areas were contoured only by a single 
observer. Two areas were contoured twice by 2 different observers. Three areas 
were contoured three times by 3 individual radiology observers. The each of last 
two remaining areas were contoured by each of the four radiology observers 
individually. The 2 areas contoured by 4 observers were PIN and Atrophy 
(simple/cystic). The 3 areas contoured by 3 observers were a PIN. The 2 areas 
contoured by 2 observers was atrophy (PAH). The remaining 16 areas contoured 
by a single observer as follow; 3 areas were normal structure, 4 areas were a PIN, 
2 areas were mixed between atrophy and PIN, 2 areas were atrophy and 5 areas 
were BPH.  
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Table 3.2. The total non-cancerous area on histology and their contoured 
frequency by radiology observers on the corresponding mpMRI image. The 
first column shows the total number of non-cancerous areas on histopathology 
digital images, which were contoured on the MRI images. The other columns 
show the total number of times the observers contoured the non-cancerous areas 
on the MRI images by the number of involved radiology observers. 
Total involved 
areas on 
digital 
histopathology 
Areas 
contoured by 
a single 
observer on 
mpMRI 
Areas 
contoured by 
two 
observers on 
mpMRI 
Areas 
contoured by 
three 
observers on 
mpMRI 
Areas 
contoured by 
four 
observers on 
mpMRI 
23 16 2 3 2 
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Chapter 4 
4 Discussion and Conclusion    
Prostate Cancer is one of the most common cancers in men, yet screening tools 
including PSA, DRE, and Transrectal Ultrasound-guided (TRUS) biopsy do not 
provide the desired high accuracy for PCa early detection and management. 
The accuracy of TRUS biopsy is still debated especially in cancer-negative 
biopsies and the medium rise in PSA levels between 4-10 ng/ml [74]. TRUS 
biopsy is seen to have a higher chance of discovering large cancer volume rather 
than higher cancer grades. However, the chance of detecting prostate tumours is 
lower in the early stages of cancer with a smaller volume. TRUS is still the 
primary imaging guiding tool for detecting PCa through biopsy [94]. Other 
studies submitted that only 28% of the prostatectomy specimen is associated with 
the original cancer grade in biopsy specimens [93]. Higher Gleason grades during 
biopsy were associated with poorly differentiated cancer after processing the 
whole prostate specimen following a prostatectomy [93]. 
The emerging MRI scanning protocol for imaging the prostate gland has a 
significant role; that is to provide a high-resolution prostate image, assist in 
detection, diagnosis, and staging the prostate tumour. Multi-parametric MRI 
(mpMRI) is not only involved in prostate cancer diagnosis but also in 
management. A controversial disagreement is present between Radiologists and 
Urologists on when mpMRI images should be prescribed [96]. Radiologists claim 
that biopsies will result in prostate haemorrhage that could take several months to 
resolve. Haemorrhage and bleeding parenchymal spots will alter prostate MRI 
assessments, which is a challenging for accurate tumour localization. The mpMRI 
could provide a highly, detailed anatomy of the prostate gland and surrounding 
structures assisting in determining the location for lesion sampling. The current 
guideline sets the MRI after a prostate biopsy associated with no tumour 
detection. On the other hand, the financial and logistic problems accompanying 
MRI are still one of the leading hindrances. Many imaging centers do not have the 
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capacity or equipment to compensate for a high number of patients for regular 
prostate screening MRI scans. 
The sensitivity and specificity of cancer detection with mpMRI reaches 80% for 
clinically significant cancer volume more than 0.5 cc in the anterior area of the 
prostate. This percentage increases to 90% for cancer located in the posterior 
gland [135]. The MRI sensitivity for detecting small prostate cancer volume (less 
than 0.5cc) is low; however, about 98% of these undetectable cancer lesions on 
MRI are low-grade prostate cancer [126, 136]. Prostate tumour volume less than 
0.5 cc is unlikely to be associated with aggressive disease, especially if it is a pure 
Gleason grade 3 and Gleason score 6 [137]. The initial aim for prostate MRI is to 
detect the most significant tumour, not every single lesion compared to breast 
MRI’s [126]. Relative to TRUS, mpMRI is more accurate in detecting gland 
volume with adjacent anatomical structures and extra-prostatic extension (EPE) 
[93]. 
The PI-RADS score system is a developing tool for assessing and differentiating 
the presence of prostate tumours and non-cancerous lesions in prostate gland MRI 
images. The probability of prostate tumour evidence is directly proportioned with 
the higher overall PI-RADS score. The PI-RADS score may also be used as a tool 
for assessing tumour aggressiveness and extra-prostatic extension. The overall PI-
RADS score 1 and 2 reveal that the probability of cancer is very unlikely. It is 
associated with the high probability of benign lesions being present. The overall 
PI-RADS score 4 and 5 are reflect the high probability of existing cancer. PI-
RADS score 3 acts as an intermediate zone between 2 possibilities [123]. Our data 
demonstrates that PI-RADS score 3 was specified in 15 radiology contours on 
mpMRI images. PI-RADS score 4 was labeled in 16 radiology contours compared 
to 6 contours labeled with PI-RADS score 5. None of these contours were 
correlated to a prostate tumour area on histopathological images. In fact, these 
contours were correlated to non-cancerous abnormalities that have been described 
in the Results section above. 
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Our study provides preliminary results on the relationship between non-cancerous 
abnormalities that could mimic cancer-like signals on prostate gland mpMRI and 
digital histopathology images. In our study, the non-rigid Target Registration 
Error (TRE) of MRI to histopathology digital images was 1.1 ± 0.7 mm [129]. In 
other studies, these relationships have not been examined with the same accuracy 
for the correlation between digital histology images and mpMRI images as 
completed in our study. 
The analysis of our study should be interpreted within the context of the study 
population. The analysis of 19 prostatectomy specimens shows that BPH, HGPIN, 
Atrophy and normal structure (CZ, AFMS) were presented in 37 radiology 
contours as potential lesions of PCa. These non-cancerous lesions had displayed 
cancer like signals on mpMRI along with an assessment of PI-RADS score 
ranging from 3 to 5 by our 4 radiology observers.  
BPH was present in 5 histopathology areas with PI-RADS score 3 and 4. PI-
RADS score 3 was assigned to 3 BPH areas out of 5. The remaining 2 areas were 
assessed as PI-RADS score 4. The BPH tissue in these 5 areas was composed of 
the glandular and stromal components. The glandular component was the major 
element of these nodules with minimal stromal tissue within BPH nodules. Visual 
qualitative assessment of these nodules revealed that glandular component 
composed of at least 70% to 80% of BPH areas with minimal stromal tissue in-
between. 
PIN is widely accepted as a known PCa precursor due to the similarity in genetic 
and cell morphology except in acini basement membrane invasion, which is 
associated with PCa. PIN includes 4 main morphological patterns: papillary, 
tufting, flat and cribriform. However, no known clinical significant impact exists 
between these different types of patterns. Their recognition arises from the 
diagnostic efficacy.  
Our data revealed that PIN was represented in 10 histopathological areas with no 
dominant or consistent pattern. Each of these patterns (tufting, papillary and flat) 
was represented in 2 areas. The cribriform pattern was represented in 1 area, and 
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mixed pattern between flat and tufting was represented in 2 areas. Another mixed 
pattern between papillary and cribriform type was present in 1 area.  
PIN features include hypercellularity, accompanied by basophilic appearance 
similar to prostate adenocarcinoma. Although the PIN glands are usually 
relatively larger in size compared to PCa glands, the basal cell layer is still abrupt, 
discontinued, or in countless cases are not visible especially with H&E stain. This 
is a characteristic feature for PCa as well. The PIN nuclear complex features 
include nuclear enlargement, crowding, and hyperchromasia are another typical 
findings in PCa cells. With PIN involvement, it is difficult to draw a clear 
separation of atypical or normal cells from nuclear presentation based on H&E 
stain only. Most of the time, additional immunohistochemical staining is required 
for further differentiation especially in prostate gland biopsy tissue. In addition to 
the loss of basal cell layer, hypercellularity and hyperchromasia are responsible 
for the decreased water permeability and restriction in fluid transfer between cells 
and between intracellular and extracellular space. This results in low water 
content in the zonal tissue similar to cancer features. The diminished water tissue 
content responsible for low signal intensity in T2W sequence and the hypointense 
signal on ADC map are the same findings in existing PCa.  
The similarity in histologic features between PIN and PCa cells such as cellular, 
nuclear and glandular features are accountable for the major portion in signal 
similarity on mpMRI.  
Atrophy was found in 7 histopathological areas. The Post-Atrophic hyperplasia 
(PAH) represented the majority of atrophic glandular changes. PAH was present 
in 4 areas, 3 areas with PAH, and one area mixed with a flat pattern of PIN. 
Another area with cystic atrophy was present with PIN features mixed with 
patterns between flat and tufting. Simple atrophy was present in 1 area. A mix 
between PAH and simple atrophic gland was present in 1 area. In general, the 
Atrophic glands are accompanied by inflammatory cells. Our data illustrates no 
large significant inflammatory cell patches in-between atrophic glands correlated 
to cancer like signal on mpMRI. The basal cell layer is diminished in glands with 
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atrophic features. Occasionally a complete lack of basal cells are seen. This 
feature presents itself in adenocarcinoma of the prostate. In the case of PAH, the 
glands appear basophilic at low power. The multiple, small acini packing is 
responsible for the hyperplastic appearance with an increase in cellularity 
compared to normal glandular tissue. The nucleolar may also display mild to 
moderate enlargement. This is also a feature of PCa and could raise confusion in 
distinguishing between PAH and prostate adenocarcinoma in the pathology 
setting. The similarities between PCa and atrophy are hypercellularity, mild to 
moderate nuclear, nucleolar enlargement, and attenuated to complete lack of basal 
cell layer could be responsible for a similar signal on mpMRI. 
The remaining 3 histopathological areas were represented by a normal or non-
pathological structure. The normal central zone glandular component was 
represented in 2 areas. The CZ glands are more complex compared to PZ glands 
with significant papillary foldings and piled up nuclei. These features increase the 
possibility for CZ glands to be diagnosed as a PIN. Anterior-fibromuscular stroma 
was present in the last remaining area.   
Our data showed that the 2 histopathology areas that were contoured by 4 
observers were atrophy and PIN. The atrophy area contained a mix of cystic and 
simple atrophy sub-type. The PIN area demonstrated a papillary pattern.   
Our study required approximately 3 extra days of processing compared to regular 
histology processing time. This processing time is for fiducial applications, apex, 
base, and mid-gland sectioning and photographing formalin sections. A set of ex 
vivo MRI images were aquired after fiducial applications. This results in the delay 
of the pathological assessment by 4-5 days. 
One of the technical challenges of the study is the registration between 
histopathology digital images and in vivo mpMRI images for the apex first cut. 
This is performed through an interactive digital technique using T2W, T1W and  
ex vivo MRI images of the prostate gland specimens after prostatectomy. 
The clinical pathology processing protocol allows only prostate mid-gland for 
whole-mount slicing. The whole-mount blocks ranged between 3 to 5 blocks per 
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prostate specimen depending on the prostate gland shape and volume. This 
procedure excluded the assessment of the apex and base of the prostate in 
correlation with mpMRI due to lack of registration between digital histopathology 
images of apex and base and mpMRI images.  
The results included multiple observers involved in the radiology contours, which 
displayed a significant inter-observer variability. Sixteen areas were contoured 
with a single observer, two areas were contoured with 2 observers, three areas 
were contoured with 3 observers and 2 areas contoured with 4 observers. Also, 
through case examinations, some areas with adenocarcinoma on the digital 
histopathology images were not associated with any radiology contours or 
recognition on mpMRI images by the 4 radiology observers. Further 
investigations are required to explore the cause of this finding as this was beyond 
the scope of this study.  
The assessment of mpMRI by 4 radiology observers was achieved using PI-
RADS score V1. The PI-RADS score V1 went through some amendments to 
increase clarity and reduce inter-observer variability. PI-RADS version 2 (V2) 
was published in 2015 as a result of these acquired changes [138]. The PI-RADS 
V2 has introduced the concepts of domain sequence in assessing prostate zonal 
anatomy [138]. DWI was assigned as a domain sequence in PZ assessment since 
T2W images were accompanied by the lack of specificity with low signal 
intensity [138]. The T2W low signal intensity may have occurred from non-
cancerous lesions such as inflammation (acute or chronic) or haemorrhage. The 
DCE sequence comes secondary to DWI in evaluating PZ. The DCE went from a 
5 points score to a positive or negative assessment, which reflects the possibility 
of the presence or absence of cancer respectively [138]. Score 3 on DWI should 
be upgraded to score 4 if corresponding DCE area shows a positive signal. 
Additionally, lesion size and shape were introduced as factors in the assessment. 
The cut-off size is ≥1.5 cm upgraded score 4 to score 5. DWI scoring categories 
went through major modification in V2 in contrast to V1. The primary sequence 
in evaluating TZ is a T2W image. The BPH in TZ accompanied by increased 
cellularity and reduced diffusion raising the suspicion for PCa presence. The cut-
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off size lesion is ≥1.5 cm between score 4 and 5, which was not considered an 
influence on V1. It is still early to evaluate how significant PI-RADS 
classification amendments will impact the clinical diagnostic performance. 
Further changes may be implemented in the future. Some studies concluded that 
the modification included in V2 has increased the sensitivity in assessing TZ 
compared to V1; however, the sensitivity of PZ assessment is slightly better with 
the V1 scoring system [139]. Our radiology observers’ assessment was performed 
according to PI-RADS V1 prior to PI-RADS V2 publication. From the 
comparison between the two versions, our data could be slightly impacted by 
increasing the sensitivity in TZ evaluation. Our data demonstrated 5 areas that 
were contoured as potential cancerous lesions in TZ on mpMRI with BPH finding 
on corresponding histopathology images. Three of these 5 areas were classified as 
score 3 and the remaining 2 were classified as PI-RADS score 4. Training and 
experience will play an essential role in interpreting prostate mpMRI images since 
there was a significant inter-observer variability between radiology observers 
associated with variable years of experience.  
Overall, our study demonstrated the relationship between false positive cancer 
like signals on prostate gland mpMRI and their corresponding pathological non-
cancerous abnormalities. Our data showed 3 major categories of non-cancerous 
lesions (Atrophy, PIN, and BPH) associated with the false positive mpMRI 
signals. The examination of these 3 major categories revealed no consistent 
pattern or subtypes responsible for this signal similarity with cancer on mpMRI 
images. Surprisingly, our data displayed no inflammation, whether, acute or 
chronic, which were associated with false positive cancer signal on mpMRI.  
The use of our current research method with a larger sample size may provide a 
vital tool in better understanding and answering the previous research questions 
regarding developing a map of non-cancerous pathology lesions and their signals 
on mpMRI. 
More research should be directed towards the relationship between multiple non-
cancerous pathology lesions present in the same zone and their signals on 
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mpMRI. The examination of areas that contain multiple mixed types of non-
cancerous abnormalities could provide essential data when correlated to mpMRI 
signals. Together with the above recommendations,  the stromal glandular ratio 
should be examined in correlation to mpMRI signals. The attenuated, disruptive 
or even complete absence of basal cell layer is an existing co-finding between 
prostate adenocarcinoma and other non-cancerous lesions such as PIN and 
atrophy. Further quantitative and qualitative assessment of the basal cell layer and 
its relationship to water permeability and fluid restriction may provide valuable 
data on basal cell presence and its impact on mpMR images. This relationship 
may have a significant input in understanding the similarity between 
adenocarcinoma and other non-cancerous lesions on mpMR images. This data, in 
collaboration with further research, can assist in improving the differentiation 
between cancerous and non-cancerous lesions, reducing the rate of false positive 
diagnosis of PCa on MRI.  
 
 
 
 
 
 
 
 
 
 
92 
 
 
Chapter 5 
5 Reference 
1. Ferlay, J., et al., Cancer incidence and mortality worldwide: Sources, 
methods and major patterns in GLOBOCAN 2012. International Journal of 
Cancer. 136(5): p. E359-E386. 
2. Hankey, B.F., et al., Cancer surveillance series: interpreting trends in 
prostate cancer--part I: Evidence of the effects of screening in recent 
prostate cancer incidence, mortality, and survival rates. J Natl Cancer 
Inst, 1999. 91(12): p. 1017-24. 
3. Center, M.M., et al., International Variation in Prostate Cancer Incidence 
and Mortality Rates. European Urology, 2012. 61(6): p. 1079-1092. 
4. 2015, C.C.S., Canadian Cancer Society’s Advisory Committee on Cancer 
Statistics. 2015. 
5. Brawley, O.W., Prostate cancer epidemiology in the United States. World 
Journal of Urology, 2012. 30(2): p. 195-200. 
6. Tao, Z.Q., et al., Epidemiology of prostate cancer: current status. Eur Rev 
Med Pharmacol Sci, 2015. 19(5): p. 805-12. 
7. Shavers, V.L.P., W.I.I.I.M.D.M.S.M.P.H. Underwood, and R.P.P. Moser, 
Race/Ethnicity, Risk Perception, and Receipt of Prostate-Specific Antigen 
Testing. Journal of the National Medical Association, 2009. 101(7): p. 
698-704. 
8. Freedland, S.J. and W.B. Isaacs, Explaining racial differences in prostate 
cancer in the United States: Sociology or biology? The Prostate. 62(3): p. 
243-252. 
9. Mahal, B.A., et al., Racial disparities in an aging population: The 
relationship between age and race in the management of African 
American men with high-risk prostate cancer. Journal of Geriatric 
Oncology. 5(4): p. 352-358. 
10. Powell, I.J., et al., Evidence supports a faster growth rate and/or earlier 
transformation to clinically significant prostate cancer in black than in 
93 
 
 
white American men, and influences racial progression and mortality 
disparity. J Urol, 2010. 183(5): p. 1792-6. 
11. Arcangeli, S., V. Pinzi, and G. Arcangeli, Epidemiology of prostate cancer 
and treatment remarks. World Journal of Radiology, 2012. 4(6): p. 241-
246. 
12. Billis, A., Latent carcinoma and atypical lesions of prostate. An autopsy 
study. Urology, 1986. 28(4): p. 324-9. 
13. Haas, G.P., et al., The Worldwide Epidemiology of Prostate Cancer: 
Perspectives from Autopsy Studies. The Canadian journal of urology, 
2008. 15(1): p. 3866-3871. 
14. Bechis, S.K., P.R. Carroll, and M.R. Cooperberg, Impact of Age at 
Diagnosis on Prostate Cancer Treatment and Survival. Journal of Clinical 
Oncology, 2011. 29(2): p. 235-241. 
15. Gandaglia, G., et al., The effect of age at diagnosis on prostate cancer 
mortality: A grade-for-grade and stage-for-stage analysis. European 
Journal of Surgical Oncology. 40(12): p. 1706-1715. 
16. Zeegers, M.P., A. Jellema, and H. Ostrer, Empiric risk of prostate 
carcinoma for relatives of patients with prostate carcinoma: a meta-
analysis. Cancer, 2003. 97(8): p. 1894-903. 
17. Hemminki, K., Familial risk and familial survival in prostate cancer. 
World J Urol, 2012. 30(2): p. 143-8. 
18. Cheng, I., et al., Socioeconomic status and prostate cancer incidence and 
mortality rates among the diverse population of California. Cancer Causes 
Control, 2009. 20(8): p. 1431-40. 
19. Rundle, A., et al., A prospective study of socioeconomic status, prostate 
cancer screening and incidence among men at high risk for prostate 
cancer. Cancer Causes & Control, 2013. 24(2): p. 297-303. 
20. Allen, N.E., et al., Animal foods, protein, calcium and prostate cancer 
risk: the European Prospective Investigation into Cancer and Nutrition. 
The British Journal of Cancer, 2008. 98(9): p. 1574-81. 
94 
 
 
21. Augustsson, K., et al., A prospective study of intake of fish and marine 
fatty acids and prostate cancer. Cancer Epidemiol Biomarkers Prev, 2003. 
12(1): p. 64-7. 
22. Vogt, T.M., et al., Serum selenium and risk of prostate cancer in U.S. 
blacks and whites. Int J Cancer, 2003. 103(5): p. 664-70. 
23. Allen, N.E., et al., A case--control study of selenium in nails and prostate 
cancer risk in British men. Br J Cancer, 2004. 90(7): p. 1392-6. 
24. Lippman, S.M., et al., Effect of selenium and vitamin E on risk of prostate 
cancer and other cancers: the Selenium and Vitamin E Cancer Prevention 
Trial (SELECT). Jama, 2009. 301(1): p. 39-51. 
25. Singh, B.P., et al., Status and Interrelationship of Zinc, Copper, Iron, 
Calcium and Selenium in Prostate Cancer. Indian Journal of Clinical 
Biochemistry, 2015. 31(1): p. 50-56. 
26. Freedland, S.J., E. Giovannucci, and E.A. Platz, Are findings from studies 
of obesity and prostate cancer really in conflict? Cancer Causes Control, 
2006. 17(1): p. 5-9. 
27. Gong, Z., et al., Obesity, diabetes, and risk of prostate cancer: results 
from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers 
Prev, 2006. 15(10): p. 1977-83. 
28. Freedland, S.J. and E.A. Platz, Obesity and prostate cancer: making sense 
out of apparently conflicting data. Epidemiol Rev, 2007. 29: p. 88-97. 
29. Marshall, J., Diet and prostate cancer prevention. World Journal of 
Urology, 2012. 30(2): p. 157-165. 
30. Freedland, S.J., et al., Obesity Is a Significant Risk Factor for Prostate 
Cancer at the Time of Biopsy. Urology, 2008. 72(5): p. 1102-1105. 
31. Allott, E.H., E.M. Masko, and S.J. Freedland, Obesity and Prostate 
Cancer: Weighing the Evidence. European Urology, 2013. 63(5): p. 800-
809. 
32. Price, A.J., et al., Insulin-like growth factor-I concentration and risk of 
prostate cancer: results from the European Prospective Investigation into 
95 
 
 
Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev, 2012. 21(9): p. 
1531-41. 
33. McNeal, J.E., Normal and pathologic anatomy of prostate. Urology, 1981. 
17(Suppl 3): p. 11-6. 
34. Everaerts, W. and A.J. Costello, Applied Anatomy of the Male Pelvis, in 
Prostate Ultrasound: Current Practice and Future Directions, R.C. Porter 
and M.E. Wolff, Editors. 2015, Springer New York: New York, NY. p. 
11-30. 
35. Mills, S.E., Histology for Pathologist. 2012, Wolters Kluwer. p. 987-1002. 
36. Fine, S.W. and V.E. Reuter, Anatomy of the prostate revisited: 
implications for prostate biopsy and zonal origins of prostate cancer. 
Histopathology. 60(1): p. 142-152. 
37. Hayward, S.W., M.A. Rosen, and G.R. Cunha, Stromal-epithelial 
interactions in the normal and neoplastic prostate. Br J Urol, 1997. 79 
Suppl 2: p. 18-26. 
38. Dauge, M.C., V. Delmas, and C.A. Mandarim de Lacerda, [Development 
of the human prostate during the first stages of fetal life. Morphometric 
study]. Bull Assoc Anat (Nancy), 1986. 70(211): p. 5-11. 
39. McNeal, J.E., Normal histiology of the prostate. American Journal of 
Surgical Pathology, 1988. 12(8): p. 619-633. 
40. McNeal, J.E., The zonal anatomy of the prostate. Prostate, 1981. 2(1): p. 
35-49. 
41. McNeal, J.E., The prostate and prostatic urethra: a morphologic 
synthesis. J Urol, 1972. 107(6): p. 1008-16. 
42. McNeal, J.E., Origin and evolution of benign prostatic enlargement. 
Invest Urol, 1978. 15(4): p. 340-5. 
43. Selman, S.H., The McNeal Prostate: A Review. Urology, 2011. 78(6): p. 
1224-1228. 
44. Bostwick, D.G. and L. Cheng, Urologic surgical pathology. Vol. 
Thirdition. 2014, Philadelphia, PA: Elsevier Saunders. 
96 
 
 
45. Lee, S., et al., Reliable identification of transition zone prostatic 
adenocarcinoma in preoperative needle core biopsy. Human Pathology, 
2013. 44(10): p. 2331-2337. 
46. Cohen, R.J., et al., Prediction of bladder neck invasion and tumor 
extension to bladder neck margin by prostatic adenocarcinoma: a 
nomogram using biopsy data including transition zone tumor morphology. 
Human pathology, 2016. 57: p. 85-90. 
47. McNeal, J.E., et al., Capsular penetration in prostate cancer. Significance 
for natural history and treatment. Am J Surg Pathol, 1990. 14(3): p. 240-
7. 
48. Ayala, A.G., et al., The prostatic capsule: does it exist? Its importance in 
the staging and treatment of prostatic carcinoma. Am J Surg Pathol, 1989. 
13(1): p. 21-7. 
49. Garcia-Monaco, R., et al., Human cadaveric specimen study of the 
prostatic arterial anatomy: implications for arterial embolization. J Vasc 
Interv Radiol, 2014. 25(2): p. 315-22. 
50. Bilhim, T., et al., Radiological anatomy of prostatic arteries. Tech Vasc 
Interv Radiol, 2012. 15(4): p. 276-85. 
51. Walsh, P.C., Radical retropubic prostatectomy with reduced morbidity: an 
anatomic approach. NCI Monogr, 1988(7): p. 133-7. 
52. Huri, E., Novel anatomical identification of nerve-sparing radical 
prostatectomy: fascial-sparing radical prostatectomy. Prostate Int, 2014. 
2(1): p. 1-7. 
53. Daneshmand, S., et al., Ethnic differences in neuroendocrine cell 
expression in normal human prostatic tissue. Urology. 65(5): p. 1008-
1012. 
54. Noordzij, M.A., et al., The prognostic influence of neuroendocrine cells in 
prostate cancer: results of a long-term follow-up study with patients 
treated by radical prostatectomy. Int J Cancer, 1995. 62(3): p. 252-8. 
55. Srigley, J.R., Benign mimickers of prostatic adenocarcinoma. Modern 
Pathology, 2004. 17(3): p. 328-348. 
97 
 
 
56. De Marzo, A.M., et al., A working group classification of focal prostate 
atrophy lesions. American Journal of Surgical Pathology, 2006. 30(10): p. 
1281-1291. 
57. Davidsson, S., et al., Inflammation, focal atrophic lesions, and prostatic 
intraepithelial neoplasia with respect to risk of lethal prostate cancer. 
Cancer Epidemiol Biomarkers Prev, 2011. 20(10): p. 2280-7. 
58. Billis, A., Prostatic atrophy. Clinicopathological significance. Int Braz J 
Urol, 2010. 36(4): p. 401-9. 
59. Ruska, K.M., J. Sauvageot, and J.I. Epstein, Histology and cellular 
kinetics of prostatic atrophy. Am J Surg Pathol, 1998. 22(9): p. 1073-7. 
60. Bostwick, D.G., et al., Architectural Patterns of High-Grade Prostatic 
Intraepithelial Neoplasia. Human Pathology, 1993. 24(3): p. 298-310. 
61. Bostwick, D.G. and L. Cheng, Precursors of prostate cancer. 
Histopathology, 2012. 60(1): p. 4-27. 
62. A. Sakr, A.B.P.E.T.W.D.G.B.W., Epidemiology of High-Grade Prostatic 
Intraepithelial Neoplasia. Scandinavian Journal of Urology and 
Nephrology, 2000. 34(205): p. 11-18. 
63. Sakr, W.A., Prostatic Intraepithelial Neoplasia: A Marker for High-Risk 
Groups and a Potential Target for Chemoprevention. European Urology, 
2012. 35(5-6): p. 474-478. 
64. Fowler, J.E., Jr., et al., Prospective study of correlations between biopsy-
detected high grade prostatic intraepithelial neoplasia, serum prostate 
specific antigen concentration, and race. Cancer, 2001. 91(7): p. 1291-6. 
65. Joniau, S., et al., Prostatic Intraepithelial Neoplasia (PIN): Importance 
and Clinical Management. European Urology, 2005. 48(3): p. 379-385. 
66. Dema, A., et al., Unusual patterns of high-grade prostatic intraepithelial 
neoplasia: morphological and immunohistochemical aspects. Virchows 
Archiv, 2011. 459: p. S278-S279. 
67. Epstein, J.I. and M. Herawi, Prostate needle biopsies containing prostatic 
intraepithelial neoplasia or atypical foci suspicious for carcinoma: 
implications for patient care. J Urol, 2006. 175(3 Pt 1): p. 820-34. 
98 
 
 
68. Lopez, J.I., Prostate adenocarcinoma detected after high-grade prostatic 
intraepithelial neoplasia or atypical small acinar proliferation. BJU Int, 
2007. 100(6): p. 1272-6. 
69. Bishara, T., D.M. Ramnani, and J.I. Epstein, High-grade prostatic 
intraepithelial neoplasia on needle biopsy - Risk of cancer on repeat 
biopsy related to number of involved cores and morphologic pattern. 
American Journal of Surgical Pathology, 2004. 28(5): p. 629-633. 
70. McNicholas, T. and D. Swallow, Benign prostatic hyperplasia. Surgery 
(Oxford), 2011. 29(6): p. 282-286. 
71. McNeal, J.E., Anatomy of the prostate and morphogenesis of BPH. Prog 
Clin Biol Res, 1984. 145: p. 27-53. 
72. Bostwick, D.G., et al., The association of benign prostatic hyperplasia and 
cancer of the prostate. Cancer, 1992. 70(1 s): p. 291-301. 
73. Kristal, A.R., et al., Race/Ethnicity, Obesity, Health Related Behaviors 
and the Risk of Symptomatic Benign Prostatic Hyperplasia: Results From 
the Prostate Cancer Prevention Trial. The Journal of Urology, 2007. 
177(4): p. 1395-1400. 
74. Gretzer, M.B. and A.W. Partin, PSA Levels and the Probability of 
Prostate Cancer on Biopsy. European Urology Supplements, 2002. 1(6): 
p. 21-27. 
75. Pezaro, C., H.H. Woo, and I.D. Davis, Prostate cancer: measuring PSA. 
Internal Medicine Journal, 2014. 44(5): p. 433-440. 
76. Balk, S.P., Y.-J. Ko, and G.J. Bubley, Biology of Prostate-Specific 
Antigen. Journal of Clinical Oncology, 2003. 21(2): p. 383-391. 
77. Adhyam, M. and A. Gupta, A Review on the Clinical Utility of PSA in 
Cancer Prostate. Indian Journal of Surgical Oncology, 2012. 3(2): p. 120-
129. 
78. Christensson, A., et al., Serum prostate specific antigen complexed to 
alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol, 1993. 
150(1): p. 100-5. 
99 
 
 
79. Gretzer, M.B. and A.W. Partin, PSA markers in prostate cancer detection. 
Urol Clin North Am, 2003. 30(4): p. 677-86. 
80. Crawford, E.D., et al., Prostate‐specific antigen 1.5–4.0 ng/mL: a 
diagnostic challenge and danger zone. BJU International, 2011. 108(11): 
p. 1743-1749. 
81. Crawford, E.D., et al., An Approach Using PSA Levels of 1.5 ng/mL as the 
Cutoff for Prostate Cancer Screening in Primary Care. Urology 
(Ridgewood, N.J.), 2016. 96: p. 116-120. 
82. Oesterling, J.E., et al., Serum prostate-specific antigen in a community-
based population of healthy men. Establishment of age-specific reference 
ranges. JAMA, 1993. 270(7): p. 860-4. 
83. Elliott, C.S., R. Shinghal, and J.C. Presti, Racial Variations in the 
Performance of Prostate Specific Antigen and Prostate Specific Antigen 
Density in the Era of Extended Prostate Biopsy Schemes. The Journal of 
Urology, 2008. 180(4): p. 1318-1324. 
84. Morgan, T.O., et al., Age-specific reference ranges for prostate-specific 
antigen in black men. The New England journal of medicine, 1996. 
335(5): p. 304-310. 
85. Walsh, P.C., Re: Long-Term Effects of Finasteride on Prostate Specific 
Antigen Levels: Results From the Prostate Cancer Prevention Trial: R. D. 
Etzioni, N. Howlader, P. A. Shaw, D. P. Ankerst, D. F. Penson, P. J. 
Goodman and I. M. Thompson J Urol, 174: 877–881, 2005. The Journal 
of Urology, 2006. 176(1): p. 409-410. 
86. Catalona, W.J., et al., Use of the percentage of free prostate-specific 
antigen to enhance differentiation of prostate cancer from benign 
prostatic disease: a prospective multicenter clinical trial. Jama, 1998. 
279(19): p. 1542-7. 
87. Luboldt, H.J., et al., Clinical usefulness of free PSA in early detection of 
prostate cancer. Onkologie, 2001. 24(1): p. 33-7. 
100 
 
 
88. Flanigan, R.C., et al., Accuracy of digital rectal examination and 
transrectal ultrasonography in localizing prostate cancer. J Urol, 1994. 
152(5 Pt 1): p. 1506-9. 
89. Djavan, B. and M. Margreiter, Biopsy standards for detection of prostate 
cancer. World Journal of Urology, 2007. 25(1): p. 11-17. 
90. Bjurlin, M.A., et al., Optimization of initial prostate biopsy in clinical 
practice: sampling, labeling and specimen processing. J Urol, 2013. 
189(6): p. 2039-46. 
91. Eskicorapci, S.Y. and L. Tuncay, Re: Diagnostic value of systematic 
biopsy methods in the investigation of prostate cancer: a systematic 
review. K. Eichler, S. Hempel, J. Wilby, L. Myers, L. M. Bachmann and J. 
Kleijnen, J Urol, 175: 1605-1612, 2006. J Urol, 2006. 176(6 Pt 1): p. 
2745; author reply 2745-6. 
92. Fütterer, J.J., et al., High-risk prostate cancer: value of multi-modality 3T 
MRI-guided biopsies after previous negative biopsies. Abdominal 
Radiology, 2012. 37(5): p. 892-896. 
93. Cam, K., et al., Accuracy of transrectal ultrasound guided prostate 
biopsy: histopathological correlation to matched prostatectomy 
specimens. Int J Urol, 2002. 9(5): p. 257-60. 
94. Washington, S.L., et al., Transrectal ultrasonography-guided biopsy does 
not reliably identify dominant cancer location in men with low-risk 
prostate cancer. BJU Int, 2012. 110(1): p. 50-5. 
95. Panebianco, V., et al., Conventional imaging and multiparametric 
magnetic resonance (MRI, MRS, DWI, MRP) in the diagnosis of prostate 
cancer. Q J Nucl Med Mol Imaging, 2012. 56(4): p. 331-42. 
96. Rosi, G., et al., Role of multiparametric MRI in the diagnosis of prostate 
cancer: update. Urologia, 2016. 83(2): p. 61-67. 
97. Boesen, L., Multiparametric MRI in detection and staging of prostate 
cancer. Dan Med J, 2017. 64(2). 
98. Futterer, J.J., et al., Prostate cancer: local staging at 3-T endorectal MR 
imaging--early experience. Radiology, 2006. 238(1): p. 184-91. 
101 
 
 
99. Beyersdorff, D., et al., MRI of prostate cancer at 1.5 and 3.0 T: 
comparison of image quality in tumor detection and staging. AJR Am J 
Roentgenol, 2005. 185(5): p. 1214-20. 
100. Bittencourt, L.K., et al., Multiparametric magnetic resonance imaging of 
the prostate: current concepts. Radiol Bras, 2014. 47(5): p. 292-300. 
101. Sankineni, S., M. Osman, and P.L. Choyke, Functional MRI in prostate 
cancer detection. Biomed Res Int, 2014. 2014: p. 590638. 
102. Yoo, S., J.K. Kim, and I.G. Jeong, Multiparametric magnetic resonance 
imaging for prostate cancer: A review and update for urologists. Korean 
Journal of Urology, 2015. 56(7): p. 487-497. 
103. Vargas, H.A., et al., Normal Central Zone of the Prostate and Central 
Zone Involvement by Prostate Cancer: Clinical and MR Imaging 
Implications. Radiology, 2012. 262(3): p. 894-902. 
104. Akin, O., et al., Transition zone prostate cancers: features, detection, 
localization, and staging at endorectal MR imaging. Radiology, 2006. 
239(3): p. 784-92. 
105. Rosenkrantz, A.B. and S.S. Taneja, Radiologist, be aware: ten pitfalls that 
confound the interpretation of multiparametric prostate MRI. AJR Am J 
Roentgenol, 2014. 202(1): p. 109-20. 
106. De Visschere, P.J., et al., Multiparametric magnetic resonance imaging 
characteristics of normal, benign and malignant conditions in the 
prostate. Eur Radiol, 2017. 27(5): p. 2095-2109. 
107. Gupta, R.T., et al., Multiparametric prostate MRI: focus on T2-weighted 
imaging and role in staging of prostate cancer. Abdom Radiol (NY), 
2016. 41(5): p. 831-43. 
108. Sala, E., et al., Endorectal MR imaging in the evaluation of seminal 
vesicle invasion: Diagnostic accuracy and multivariate feature analysis. 
Radiology, 2006. 238(3): p. 929-937. 
109. Ren, J., et al., Seminal vesicle invasion in prostate cancer: prediction with 
combined T2-weighted and diffusion-weighted MR imaging. Eur Radiol, 
2009. 19(10): p. 2481-6. 
102 
 
 
110. Baliyan, V., et al., Diffusion weighted imaging: Technique and 
applications. World J Radiol, 2016. 8(9): p. 785-798. 
111. Ueno, Y., et al., Computed diffusion-weighted imaging using 3-T magnetic 
resonance imaging for prostate cancer diagnosis. European Radiology, 
2013. 23(12): p. 3509-3516. 
112. Provenzale, J.M., et al., Use of MR exponential diffusion-weighted images 
to eradicate T2 "shine-through" effect. AJR Am J Roentgenol, 1999. 
172(2): p. 537-9. 
113. Vargas, H.A., et al., Diffusion-weighted endorectal MR imaging at 3 T for 
prostate cancer: tumor detection and assessment of aggressiveness. 
Radiology, 2011. 259(3): p. 775-84. 
114. Nicholson, B., G. Schaefer, and D. Theodorescu, Angiogenesis in prostate 
cancer: biology and therapeutic opportunities. Cancer Metastasis Rev, 
2001. 20(3-4): p. 297-319. 
115. Thompson, J., et al., The role of magnetic resonance imaging in the 
diagnosis and management of prostate cancer. BJU Int, 2013. 112 Suppl 
2: p. 6-20. 
116. Turkbey, B., B. Turkbey, and P.L. Choyke, Multiparametric MRI and 
prostate cancer diagnosis and risk stratification. Current opinion in 
urology, 2012. 22(4): p. 310-315. 
117. Verma, S., et al., Overview of dynamic contrast-enhanced MRI in prostate 
cancer diagnosis and management. AJR Am J Roentgenol, 2012. 198(6): 
p. 1277-88. 
118. Isebaert, S., et al., Evaluation of semi-quantitative dynamic contrast-
enhanced MRI parameters for prostate cancer in correlation to whole-
mount histopathology. Eur J Radiol, 2012. 81(3): p. e217-22. 
119. Hansford, B.G., et al., Dynamic Contrast-enhanced MR Imaging Curve-
type Analysis: Is It Helpful in the Differentiation of Prostate Cancer from 
Healthy Peripheral Zone? Radiology, 2015. 275(2): p. 448-457. 
103 
 
 
120. Cuenod, C.A. and D. Balvay, Perfusion and vascular permeability: basic 
concepts and measurement in DCE-CT and DCE-MRI. Diagn Interv 
Imaging, 2013. 94(12): p. 1187-204. 
121. Pinto, P.A., et al., Magnetic resonance imaging/ultrasound fusion guided 
prostate biopsy improves cancer detection following transrectal 
ultrasound biopsy and correlates with multiparametric magnetic 
resonance imaging. J Urol, 2011. 186(4): p. 1281-5. 
122. Westphalen, A.C. and A.B. Rosenkrantz, Prostate imaging reporting and 
data system (PI-RADS): reflections on early experience with a 
standardized interpretation scheme for multiparametric prostate MRI. 
AJR Am J Roentgenol, 2014. 202(1): p. 121-3. 
123. Clements, R., et al., ESUR prostate MR guidelines 2012. European 
Radiology, 2012. 22(4): p. 746-757. 
124. Rothke, M., et al., [PI-RADS classification: structured reporting for MRI 
of the prostate]. Rofo, 2013. 185(3): p. 253-61. 
125. Roethke, M.C., et al., Evaluation of the ESUR PI-RADS scoring system for 
multiparametric MRI of the prostate with targeted MR/TRUS fusion-
guided biopsy at 3.0 Tesla. European Radiology, 2014. 24(2): p. 344-352. 
126. Junker, D., et al., Evaluation of the PI-RADS scoring system for mpMRI of 
the prostate: a whole-mount step-section analysis. World Journal of 
Urology, 2015. 33(7): p. 1023-1030. 
127. Roethke, M.C., et al., Evaluation of the ESUR PI-RADS scoring system for 
multiparametric MRI of the prostate with targeted MR/TRUS fusion-
guided biopsy at 3.0 Tesla. European Radiology, 2014. 24(2): p. 344-352. 
128. Dickinson, L., et al., Magnetic resonance imaging for the detection, 
localisation, and characterisation of prostate cancer: recommendations 
from a European consensus meeting. Eur Urol, 2011. 59(4): p. 477-94. 
129. Ward, A.D., et al., Prostate: Registration of digital histopathologic images 
to in vivo MR images acquired by using endorectal receive coil. 
Radiology, 2012. 263(3): p. 856-864. 
104 
 
 
130. Ward, A.D., et al., Prostate: registration of digital histopathologic images 
to in vivo MR images acquired by using endorectal receive coil. 
Radiology, 2012. 263(3): p. 856-64. 
131. Ward, A.D., et al., Registration of In Vivo Prostate Magnetic Resonance 
Images to Digital Histopathology Images, in Prostate Cancer Imaging. 
Computer-Aided Diagnosis, Prognosis, and Intervention: International 
Workshop, Held in Conjunction with MICCAI 2010, Beijing,China, 
September 24, 2010. Proceedings, A. Madabhushi, et al., Editors. 2010, 
Springer Berlin Heidelberg: Berlin, Heidelberg. p. 66-76. 
132. Gibson, E., et al., Registration of prostate histology images to ex vivo MR 
images via strand‐shaped fiducials. Journal of Magnetic Resonance 
Imaging, 2012. 36(6): p. 1402-1412. 
133. Gibson, E., et al., 3D prostate histology image reconstruction: Quantifying 
the impact of tissue deformation and histology section location. Journal of 
Pathology Informatics, 2013. 4(1): p. 31-31. 
134. Gibson, E., et al., Toward prostate cancer contouring guidelines on MRI: 
dominant lesion gross and clinical target volume coverage via accurate 
histology fusion. International Journal of Radiation 
OncologyBiologyPhysics, 2016. 
135. Villers, A. and A. Ouzzane, Multimodality MRI-Guided Targeting, in 
Imaging and Focal Therapy of Early Prostate Cancer, J.T. Polascik, 
Editor. 2013, Humana Press: Totowa, NJ. p. 133-140. 
136. Moore, C.M., et al., Image-Guided Prostate Biopsy Using Magnetic 
Resonance Imaging–Derived Targets: A Systematic Review. European 
Urology, 2013. 63(1): p. 125-140. 
137. Wolters, T., et al., A critical analysis of the tumor volume threshold for 
clinically insignificant prostate cancer using a data set of a randomized 
screening trial. J Urol, 2011. 185(1): p. 121-5. 
138. Weinreb, J.C., et al., PI-RADS Prostate Imaging – Reporting and Data 
System: 2015, Version 2. European Urology, 2016. 69(1): p. 16-40. 
105 
 
 
139. Polanec, S., et al., Head-to-head comparison of PI-RADS v2 and PI-RADS 
v1. European Journal of Radiology, 2016. 85(6): p. 1125-1131. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
106 
 
 
Curriculum Vitae 
  
107 
 
 
Mena Gaed 
EDUCATION 
2012-2018 Master of Science, Pathology M.Sc. 
University of Western, London, Ontario 
 
2006 Bachelor of Medicine and Bachelor of Surgery MB. BCH 
Cairo University, Cairo, Egypt  
 
POST-GRADUATE QUALIFICATIONS 
2013 National Assessment Collaboration (NAC) Objective  
                        Structured Clinical Examination 
2011 Ultra Sound Operator 
2011 MRI Operator 
2010 Centre for the Evaluation of Health Professional Educated       
                        Abroad CEHPEA 
2009 Medical Council of Canada Qualifying Exam One MCCQ1 
2008 Medical Council of Canada Evaluation Exam MCCEE 
 
RELEVANT WORK EXPERIENCE 
 
2010-P Pathologist Research Assistant 
 London Health Science Centre/ Robarts Research Institute 
 
2015-P Ontario Telemedicine Network (OTN) 
 Physician Assistant 
 
2005-2016 Central Mall Drug Mart  
 Pharmacy Office Manager   
 
OBSERVERSHIP 
 
2014 London Health Science Centre 
Summer          Anatomical Pathology Observer-ship 
 
2013-2014 Windsor River Walk-In Clinic 
  Family Medicine Observer-ship 
 
2005-2006 Central Mall Medical Centre 
Family Medicine Observer-ship 
 
 
 
108 
 
 
PUBLICATIONS 
 
JOURNALS  
 
1. E. Gibson, M. Gaed, T. Hrinivich, J.A. Gómez, M. Moussa, C. Romagnoli, J. 
Mandel, M. Bastian-Jordan, D.W. Cool S. Ghoul, S.E. Pautler, J.L. Chin, C. 
Crukley, G. S. Bauman, A. Fenster, A.D. Ward. Multiparametric MR imaging 
of prostate cancer foci: assessing the detectability and localizability of 
Gleason 7 peripheral zone cancers based on image contrasts. Medical Imaging 
2014: Digital Pathology, SPIE 9041. [DOI: 10.1117/12.2043324] 
2. M. Salarian, E. Gibson, M. Shahedi, M. Gaed, J.A. Gómez, M. Moussa, C. 
Romagnoli, D.W. Cool, M. Bastian-Jordan, J.L. Chin, S.E. Pautler, G. S. 
Bauman. Accuracy and variability of tumour burden measurement on multi-
parametric MRI. Medical Imaging 2014: Digital Pathology, SPIE 9041. 
[DOI: 10.1117/12.2043716] 
3. E. Gibson, C. Crukley, M. Gaed, J.A. Gómez, M. Moussa, J.L. Chin, G.S. 
Bauman, A. Fenster, A.D. Ward. Registration of prostate histology images to 
ex vivo MR images via strand-shape fiducials. Journal of Magazine of 
Reasoning Imaging, 2012. [DOI: 10.1002/jmri.23767] 
4. E. Gibson, M. Gaed, J. A. Gómez, M. Moussa, S. Pautler, J. L. Chin, 
C. Crukley, G. S. Bauman, A. Fenster, A. D. Ward. 3D prostate histology 
image reconstruction: quantifying the impact of tissue deformation and 
histology section location. Journal of Pathology Informatics, 2013.  
5. E. Gibson, M. Gaed, J. A. Gómez, M. Moussa, C. Romagnoli, S. Pautler, 
J. L. Chin, C. Crukley, G. S. Bauman, A. Fenster, A. D. Ward. 3D prostate 
histology reconstruction: an evaluation of image-based and fiducial-based 
algorithms. Medical Physics, 40(9), 093501, 2013. [10.1118/1.4816946]  
6. F. Imani, P. Abolmaesumi, E. Gibson, A. Khojaste, M. Gaed, M. Moussa, 
J. A. Gómez, C. Romagnoli, D. R. Siemens, M. Leviridge, S. Chang, Fenster, 
A. D. Ward, P. Mousavi. Ultrasound-based characterization of prostate 
109 
 
 
cancer: an in vivo clinical feasibility study. In Medical Image Computing and 
Computer-Assisted Intervention. 2013;16(Pt2):279-86 
7. L. Gorelick, O. Veskler, M. Gaed, J.A. Gómez, M. Moussa, G.S. Bauman, A. 
Fenster, A.D. Ward. Prostate Histopathology: Learning Tissue Component 
Histograms for Cancer Detection and Classification. Transactions on Medical 
Imaging, May 2013 
 
BOOK CHAPTERS 
1. Gibson, C. Crukley, M. Gaed, J. A. Gómez-Lemus, M. Moussa, 
C. Romagnoli, S. Pautler, J. Chin, G. Bauman, A. Fenster, A. D. Ward. 3D 
registration of whole-mount prostate histology images to ex vivo magnetic 
resonance images using strand-shaped fiducials. In Abdomen and Thoracic 
Imaging: An Engineering & Clinical Perspective, A. S. El-Baz, L. Saba, 
J. Suri. 
  
ORAL PRESENTATIONS 
 
1. M. Gaed. MRI Signaling to Non-Cancerous Abnormalities That Could Mimic 
Cancer in Prostate. Journal Club Oral Presentations, Department of Pathology, 
The University of Western Ontario; London, Canada, April 01, 2014.  
2. M. Gaed. Prostate Cancer Subtype & Grade In Correlation With MRI. Journal 
Club Oral Presentations, Department of Pathology, The University of Western 
Ontario; London, Canada, April 09, 2013.    
3. E.Gibson, I. Rachinsky, M. Gaed, C. Romagnoli, T. Lee, C. Crukley, J.A. 
Gómez-Lemus, M. Moussa, J.L. Chin, G. Bauman, A. Fenster, A.D. Ward. 
Ontario's first F fluorocholine prostate PET images: histology and multi-
parametric MRI correlation. Robarts Research Institute, Department of 
Medical Imaging, The University of Western Ontario; Lawson Health 
Research Institute; Department of Medical Biophysics, Department of 
110 
 
 
Pathology, Department of Urology, Department of Oncology, The University 
of Western Ontario; Baines Imaging Research Laboratories, London Health 
Sciences Centre, London, Canada, April 2012. 
 
4. E. Gibson, C. Crukley, M. Gaed, J. A. Gómez-Lemus, M. Moussa, J. L.Chin, 
G. Bauman, A. Fenster, A. D. Ward. Validation of direct registration of 
whole-mount prostate digital histopathology to ex vivo MR images, Medical 
Image Computing and Computer-Assisted Intervention (MICCAI) Prostate 
Cancer Imaging Workshop, Toronto, Canada, September 2011. (Oral 
presentation by E. Gibson and J. L. Chin) 
CONFERENCE MANUSCRIPTS 
1. E. Gibson, C. Crukley, M. Gaed, J. A. Gómez-Lemus, M. Moussa, J. L. Chin, 
G. Bauman, A. Fenster, A. D. Ward. Validation of direct registration of 
whole-mount prostate digital histopathology to ex vivo MR images, Medical 
Image Computing and Computer-Assisted Intervention (MICCAI) Prostate 
Cancer Imaging Workshop, Prostate cancer imaging: image analysis and 
image-guided interventions, Lecture Notes in Computer Science, 6963(2011) 
pp 134-145, 2011. 
2. E. Gibson, C. Crukley, V. Karnik, M. Gaed, J. A. Gómez-Lemus, M.Moussa, 
J. L. Chin, G. Bauman, A. Fenster, A. D. Ward. Co-registration framework for 
histology-registration-based validation of fused multimodality prostate cancer 
imaging, IEEE International conference on Intelligent Computation and Bio-
Medical Instrumentation, Wuhan, China, December 2011. 
 
PEER-REVIEWED CONFERENCE PROCEEDINGS 
1. E. Gibson, M. Gaed, J. A. Gómez-Lemus, M. Moussa, C. Romagnoli, 
J. L. Chin, C. Crukley, G. S. Bauman, A. Fenster, A. D. Ward. 3D prostate 
histology reconstruction: an evaluation of image-based and fiducial-based 
algorithms. In SPIE Medical Imaging: Digital Pathology, 8676, pp. 86760A, 
111 
 
 
Orlando, USA, Mar. 2013. (podium presentation by E. Gibson) 
[10.1117/12.2006897]. 
2. E. Gibson, M. Gaed, T. Hrinivich, J. A. Gómez, M. Moussa, C. Romagnoli, 
J. Mandel, M. Bastian-Jordan, D. Cool, S. Ghoul, S. Pautler, J. L. Chin, 
C. Crukley, G. S.  Bauman, A. Fenster, A. D. Ward. Multiparametric MR 
imaging of prostate cancer foci: assessing the detectability and localizability 
of Gleason 7 peripheral zone cancers based on image contrasts. In SPIE 
Medical Imaging, San Diego, USA, Feb. 2014.   
3. M. Salarian, E. Gibson, M. Shahedi, M. Gaed, J. A. Gómez, M. Moussa, 
C. Romagnoli, D. W. Cool, M. Bastian-Jordan, J. L. Chin, S. Pautler, 
G. S. Bauman, A. D. Ward. Accuracy and variability of tumour burden 
measurement on multi-parametric MRI. In SPIE Medical Imaging, San Diego, 
USA, Feb. 2014. (podium presentation by M. Salarian) 
4. M. Salarian, M. Shahedi, E. Gibson, M. Gaed, J. A. Gómez-Lemus, 
M. Moussa, G. S. Bauman, A. D. Ward. Toward quantitative digital 
histopathology for prostate cancer: comparison of inter-slide interpolation 
methods for tumour measurement. In SPIE Medical Imaging: Digital 
Pathology, 8676, pp. 86760F, Orlando, USA, Mar. 2013. (podium 
presentation by M. Salarian) [10.1117/12.2007103]  
5. T. Hrinivich, E. Gibson, M. Gaed, J. A. Gómez, M. Moussa, C. McKenzie, 
G. Bauman, A. D. Ward, A. Fenster, E. Wong. A dimensionless dynamic 
contrast enhanced MRI parameter for intra-prostatic tumour target volume 
delineation: initial comparison with histology. In SPIE Medical Imaging, San 
Diego, USA, Feb. 2014.  
 
PEER-REVIEWED CONFERENCE ABSTRACTS 
1. E. Gibson, M. Gaed, J. A. Gómez, M. Moussa, C. Romagnoli, J. Mandel, 
M. Bastian-Jordan, S. Ghoul, D. Cool, S. Pautler, J. L. Chin, C. Crukley, 
G. S. Bauman, A. Fenster, A. D. Ward. Toward contouring guidelines for 
112 
 
 
prostate cancer focal therapy planning on MRI: characterisation of tumour 
boundary contrast via accurate pathology fusion. Ann. Meeting Radiological 
Society of North America, Chicago, USA, Dec. 2013. (podium presentation 
by E. Gibson)  
2. E. Gibson, M. Gaed, J. A. Gómez, M. Moussa, C. Romagnoli, J. Mandel, 
M. Bastian-Jordan, S. Ghoul, D. Cool, S. Pautler, J. L. Chin, C. Crukley, 
G. S. Bauman, A. Fenster, A. D. Ward. Toward contouring guidelines for 
prostate cancer focal therapy planning on MRI: characterisation of tumour 
boundary contrast via accurate pathology fusion. Australian-Canadian Prostate 
Cancer Research Alliance Symposium, Port Douglas, Australia, Aug. 2013. 
(Prostate Cancer Canada travel award; one of seven posters selected for 
podium presentation)  
3. G. Bauman, J. Mandel, C. Romagnoli, I. Rachinsky, A. D. Ward, E. Gibson, 
M. Gaed, M. Moussa, J. Gómez-Lemus, J. Chin, S. Pautler, J. Butler, 
E. Wong, T.-Y. Lee. 18-fluorocholine imaging of localized prostate cancer: 
first experience with hybrid PET/MRI. Ann. Meeting Canadian Organization 
of Medical Physicists-Canadian Association of Radiation Oncology, 
Montreal, Canada, Sep. 2013.  
4. M. Salarian, M. Shahedi, E. Gibson, M. Gaed, J. A. Gómez, M. Moussa, 
D. W. Cool, C. Romagnoli, G. S. Bauman, A. D. Ward. Imaging validation 
and quantitative pathology in prostate cancer: shape interpolation methods for 
tumour measurement. Ann. Meeting Canadian Organization of Medical 
Physicists-Canadian Association of Radiation Oncology, Montreal, Canada, 
Sep. 2013. (podium presentation by M. Salarian) 
 
LOCAL/PROVINCIAL/NATIONAL CONFERENCE ABSTRACTS 
1. E. Gibson, M. Gaed, J. A. Gómez, M. Moussa, C. Romagnoli, J. Mandel, 
M. Bastian-Jordan, S. Ghoul, D. Cool, S. Pautler, J. L. Chin, C. Crukley, 
G. S. Bauman, A. Fenster, A. D. Ward. Toward contouring guidelines for 
prostate cancer focal therapy planning on MRI: characterisation of tumour 
113 
 
 
boundary contrast via accurate pathology fusion. Canadian Cancer Research 
Conference, Toronto, Canada, Nov. 2013.  
2. E. Gibson, M. Gaed, J. A. Gómez, M. Moussa, C. Romagnoli, J. Mandel, 
M. Bastian-Jordan, S. Ghoul, D. Cool, S. Pautler, J. L. Chin, C. Crukley, 
G. S. Bauman, A. Fenster, A. D. Ward. Toward contouring guidelines for 
prostate cancer focal therapy planning on MRI: characterisation of tumour 
boundary contrast via accurate pathology fusion. Oncology Research and 
Education Day, London, Canada, Jun. 2013.  
3. E. Gibson, M. Gaed, J. A. Gómez, M. Moussa, C. Romagnoli, J. Mandel, 
M. Bastian-Jordan, S. Ghoul, D. Cool, S. Pautler, J. L. Chin, C. Crukley, 
G. S. Bauman, A. Fenster, A. D. Ward. Toward contouring guidelines for 
prostate cancer focal therapy planning on MRI: characterisation of tumour 
boundary contrast via accurate pathology fusion. London Imaging Discovery, 
London, Canada, Jun. 2013. (podium presentation by E. Gibson; honourable 
mention) 
4. M. Salarian, M. Shahedi, E. Gibson, M. Gaed, J. A. Gómez, M. Moussa, 
D. W. Cool, C. Romagnoli, G. S. Bauman, A. D. Ward. Imaging validation 
and quantitative pathology in prostate cancer: shape interpolation methods for 
tumour measurement. Canadian Cancer Research Conference, Toronto, 
Canada, Nov. 2013.  
 
POSTER PRESENTATIONS 
1. E. Gibson, C. Crukley, V. Karnik, M. Gaed, J. A. Gómez-Lemus, M. Moussa, 
J. L. Chin, G. Bauman, A. Fenster, A. D. Ward. Co-registration framework for 
histology-registration-based validation of fused multimodality prostate cancer 
imaging, IEEE International conference on Intelligent Computation and Bio-
Medical Instrumentation, presented at Wuhan, China, December 2011. 
2. E. Gibson, C. Crukley, V. Karnik, M. Gaed, J. A. Gómez, M. Moussa, J. L. 
Chin, G. Bauman, A. Fenster, A. D. Ward, From digital histopathology to in 
114 
 
 
vivo imaging: 3D reconstruction, registration and validation. To be presented 
at Canadian Cancer Research Conference, Toronto, Canada, November 2011. 
 
3. E. Gibson, C. Crukley, V. Karnik, M. Gaed, J. A. Gómez, M. Moussa, J. L. 
Chin, G. Bauman, A. Fenster, A. D. Ward.  3D reconstruction of prostate 
histopathology for co-registration with in vivo imaging. Presented at 
Pathology Visions, San Diego, USA, October 2011. 
 
 
 
 
 
 
 
